JP2022552693A - Pd-l1拮抗薬化合物 - Google Patents
Pd-l1拮抗薬化合物 Download PDFInfo
- Publication number
- JP2022552693A JP2022552693A JP2022522850A JP2022522850A JP2022552693A JP 2022552693 A JP2022552693 A JP 2022552693A JP 2022522850 A JP2022522850 A JP 2022522850A JP 2022522850 A JP2022522850 A JP 2022522850A JP 2022552693 A JP2022552693 A JP 2022552693A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- alkylene
- alkyl group
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 785
- 229940123751 PD-L1 antagonist Drugs 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 114
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 61
- 229910052736 halogen Inorganic materials 0.000 claims description 48
- 150000002367 halogens Chemical class 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 48
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 201000010099 disease Diseases 0.000 claims description 40
- 125000005843 halogen group Chemical group 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims description 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 230000000155 isotopic effect Effects 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 396
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 234
- 230000015572 biosynthetic process Effects 0.000 description 232
- 238000003786 synthesis reaction Methods 0.000 description 232
- 238000005481 NMR spectroscopy Methods 0.000 description 223
- 239000000243 solution Substances 0.000 description 167
- 238000006243 chemical reaction Methods 0.000 description 147
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 120
- 239000007787 solid Substances 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 70
- -1 small molecule compounds Chemical class 0.000 description 69
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 239000012074 organic phase Substances 0.000 description 53
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 52
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- 238000010898 silica gel chromatography Methods 0.000 description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 30
- 229940126639 Compound 33 Drugs 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 27
- 239000008346 aqueous phase Substances 0.000 description 26
- 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 25
- 239000003208 petroleum Substances 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- 125000002947 alkylene group Chemical group 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 22
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 21
- NHAYDXCUCXRAMF-UHFFFAOYSA-N (4-methoxycarbonylcyclohexyl)azanium;chloride Chemical compound Cl.COC(=O)C1CCC(N)CC1 NHAYDXCUCXRAMF-UHFFFAOYSA-N 0.000 description 20
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 239000012299 nitrogen atmosphere Substances 0.000 description 17
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 125000004122 cyclic group Chemical group 0.000 description 16
- 230000002439 hemostatic effect Effects 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 101000810330 Arabidopsis thaliana Eukaryotic translation initiation factor 3 subunit E Proteins 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
- 239000012230 colorless oil Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 11
- 125000006413 ring segment Chemical group 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 10
- KJIODOACRIRBPB-UHFFFAOYSA-N 4-bromo-1h-indazole Chemical compound BrC1=CC=CC2=C1C=NN2 KJIODOACRIRBPB-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 229940126208 compound 22 Drugs 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- PLYVYQNMLHQMCW-UHFFFAOYSA-N methyl 4-aminobicyclo[2.2.2]octane-1-carboxylate;hydrochloride Chemical compound [Cl-].C1CC2([NH3+])CCC1(C(=O)OC)CC2 PLYVYQNMLHQMCW-UHFFFAOYSA-N 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 238000006268 reductive amination reaction Methods 0.000 description 9
- 238000010189 synthetic method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- IRPWVEBIMPXCAZ-UHFFFAOYSA-N 1,3-dibromo-2-chlorobenzene Chemical compound ClC1=C(Br)C=CC=C1Br IRPWVEBIMPXCAZ-UHFFFAOYSA-N 0.000 description 7
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 229910003827 NRaRb Inorganic materials 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 238000005886 esterification reaction Methods 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QPMSJEFZULFYTB-PGMHMLKASA-N (3r)-pyrrolidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCNC1 QPMSJEFZULFYTB-PGMHMLKASA-N 0.000 description 6
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 5
- YMXQYZABFWVXEK-UHFFFAOYSA-N 4-bromo-2-methoxybenzaldehyde Chemical compound COC1=CC(Br)=CC=C1C=O YMXQYZABFWVXEK-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- DNFAPUBVCHTMJX-KYOXOEKESA-N CCl.N[C@@H]1CC[C@H](CC1)C(=O)O Chemical compound CCl.N[C@@H]1CC[C@H](CC1)C(=O)O DNFAPUBVCHTMJX-KYOXOEKESA-N 0.000 description 5
- 239000005909 Kieselgur Substances 0.000 description 5
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 4
- OCSKCBIGEMSDIS-UHFFFAOYSA-N 1,3-dibromo-2-methylbenzene Chemical group CC1=C(Br)C=CC=C1Br OCSKCBIGEMSDIS-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 125000006165 cyclic alkyl group Chemical group 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical group CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 3
- UCDVGKULVDTSRP-TYSVMGFPSA-N COC(=O)[C@@H]1CC[C@H]1N.Cl Chemical compound COC(=O)[C@@H]1CC[C@H]1N.Cl UCDVGKULVDTSRP-TYSVMGFPSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 3
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000010931 ester hydrolysis Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- HRMRQBJUFWFQLX-SSDOTTSWSA-N (3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](C(O)=O)C1 HRMRQBJUFWFQLX-SSDOTTSWSA-N 0.000 description 2
- YCGQPIRMLGEWMW-UHFFFAOYSA-N 1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN(C)C)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 YCGQPIRMLGEWMW-UHFFFAOYSA-N 0.000 description 2
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 2
- YRTFLDFDKPFNCJ-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCN1CCCC1 YRTFLDFDKPFNCJ-UHFFFAOYSA-N 0.000 description 2
- 125000005955 1H-indazolyl group Chemical group 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- VGOALPIDEXVYQI-UHFFFAOYSA-N 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-n-[3-imidazol-1-yl-5-(trifluoromethyl)phenyl]-4-methylbenzamide Chemical compound C1=C(C#CC=2N3N=CC=CC3=NC=2)C(C)=CC=C1C(=O)NC(C=C(C=1)C(F)(F)F)=CC=1N1C=CN=C1 VGOALPIDEXVYQI-UHFFFAOYSA-N 0.000 description 2
- UNSHMXUHOHBLIQ-UHFFFAOYSA-N 3-[4-chloro-3-(2-methylphenoxy)naphthalen-1-yl]-6-(trifluoromethyl)-1H-pyrimidine-2,4-dione Chemical compound ClC1=C(C=C(C2=CC=CC=C12)N1C(NC(=CC1=O)C(F)(F)F)=O)OC1=C(C=CC=C1)C UNSHMXUHOHBLIQ-UHFFFAOYSA-N 0.000 description 2
- WPDXAMRGYMDTOV-UHFFFAOYSA-N 3-bromo-2-methylphenol Chemical compound CC1=C(O)C=CC=C1Br WPDXAMRGYMDTOV-UHFFFAOYSA-N 0.000 description 2
- FVZODFVCIDBDGS-UHFFFAOYSA-N 3-bromo-4-chloroaniline Chemical compound NC1=CC=C(Cl)C(Br)=C1 FVZODFVCIDBDGS-UHFFFAOYSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- FCBOUJYKAGWYQM-DEOSSOPVSA-N 6-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]-n-(2-phenoxyethyl)-2-(3,4,5-trimethoxyphenyl)pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(N[C@H](CO)CC=3C=CC=CC=3)N=2)C(=O)NCCOC=2C=CC=CC=2)=C1 FCBOUJYKAGWYQM-DEOSSOPVSA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 2
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940126082 compound 92a Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical group CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 239000003350 kerosene Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 1
- SLTBMTIRYMGWLX-XMMPIXPASA-N (2r)-2-[(4-chloroanilino)carbamoylamino]-3-(1h-indol-3-yl)-n-(2-phenylethyl)propanamide Chemical compound C1=CC(Cl)=CC=C1NNC(=O)N[C@@H](C(=O)NCCC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 SLTBMTIRYMGWLX-XMMPIXPASA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- NXILIHONWRXHFA-MRVPVSSYSA-N (3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](C(O)=O)C1 NXILIHONWRXHFA-MRVPVSSYSA-N 0.000 description 1
- YQGDEPYYFWUPGO-GSVOUGTGSA-N (3r)-4-amino-3-hydroxybutanoic acid Chemical compound NC[C@H](O)CC(O)=O YQGDEPYYFWUPGO-GSVOUGTGSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- NXILIHONWRXHFA-QMMMGPOBSA-N (3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](C(O)=O)C1 NXILIHONWRXHFA-QMMMGPOBSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- QPMSJEFZULFYTB-WCCKRBBISA-N (3s)-pyrrolidin-3-ol;hydrochloride Chemical compound Cl.O[C@H]1CCNC1 QPMSJEFZULFYTB-WCCKRBBISA-N 0.000 description 1
- AFMGAVDATRJOJG-GUYCJALGSA-N (3s,5s)-3-methyl-5-[(4-phenylphenyl)methyl]pyrrolidin-2-one Chemical group N1C(=O)[C@@H](C)C[C@H]1CC1=CC=C(C=2C=CC=CC=2)C=C1 AFMGAVDATRJOJG-GUYCJALGSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- HOBJEFOCIRXQKH-SCSAIBSYSA-N (5r)-5-(hydroxymethyl)pyrrolidin-2-one Chemical compound OC[C@H]1CCC(=O)N1 HOBJEFOCIRXQKH-SCSAIBSYSA-N 0.000 description 1
- QFOSFXPTXNRRMF-BYPYZUCNSA-N (5s)-5-(bromomethyl)pyrrolidin-2-one Chemical compound BrC[C@@H]1CCC(=O)N1 QFOSFXPTXNRRMF-BYPYZUCNSA-N 0.000 description 1
- HOBJEFOCIRXQKH-BYPYZUCNSA-N (5s)-5-(hydroxymethyl)pyrrolidin-2-one Chemical compound OC[C@@H]1CCC(=O)N1 HOBJEFOCIRXQKH-BYPYZUCNSA-N 0.000 description 1
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- GPPYYGWYUFOWSR-UHFFFAOYSA-N 1,3-dibromo-2-fluorobenzene Chemical compound FC1=C(Br)C=CC=C1Br GPPYYGWYUFOWSR-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- XTDTYSBVMBQIBT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanol Chemical compound CC(O)C1=CC=C(Br)C=C1 XTDTYSBVMBQIBT-UHFFFAOYSA-N 0.000 description 1
- QLMFTKHAIDWIDC-UHFFFAOYSA-N 1-(4-bromophenyl)propan-1-ol Chemical compound CCC(O)C1=CC=C(Br)C=C1 QLMFTKHAIDWIDC-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- CTPUUDQIXKUAMO-UHFFFAOYSA-N 1-bromo-3-iodobenzene Chemical compound BrC1=CC=CC(I)=C1 CTPUUDQIXKUAMO-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- XIRRDAWDNHRRLB-UHFFFAOYSA-N 2,6-dibromoaniline Chemical compound NC1=C(Br)C=CC=C1Br XIRRDAWDNHRRLB-UHFFFAOYSA-N 0.000 description 1
- KBLLYABRMLFXFZ-UHFFFAOYSA-N 2,6-dibromobenzonitrile Chemical compound BrC1=CC=CC(Br)=C1C#N KBLLYABRMLFXFZ-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- MZYXHLMULHPGKX-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)ethanamine Chemical compound NCCC1=NN=NN1 MZYXHLMULHPGKX-UHFFFAOYSA-N 0.000 description 1
- SKEXQIJIXQSFRX-MRVPVSSYSA-N 2-[(3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@H](CC(O)=O)C1 SKEXQIJIXQSFRX-MRVPVSSYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- IHXBNSUFUFFBRL-UHFFFAOYSA-N 2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexyl]acetic acid Chemical compound CC(C)(C)OC(=O)NC1CCC(CC(O)=O)CC1 IHXBNSUFUFFBRL-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- FOCCSIJMXBTKHD-UHFFFAOYSA-N 2-bromo-1-chloro-4-fluorobenzene Chemical compound FC1=CC=C(Cl)C(Br)=C1 FOCCSIJMXBTKHD-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- UTVCLUZQPSRKMY-UHFFFAOYSA-N 2-chloro-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1Cl UTVCLUZQPSRKMY-UHFFFAOYSA-N 0.000 description 1
- CZNFABVUVHWEJF-UHFFFAOYSA-N 2-fluoro-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1F CZNFABVUVHWEJF-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DUKKNDLIWRYBCT-UHFFFAOYSA-N 3-bromo-2-chlorophenol Chemical compound OC1=CC=CC(Br)=C1Cl DUKKNDLIWRYBCT-UHFFFAOYSA-N 0.000 description 1
- GRXMMIBZRMKADT-UHFFFAOYSA-N 3-bromo-4-methylaniline Chemical compound CC1=CC=C(N)C=C1Br GRXMMIBZRMKADT-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- CEAVPXDEPGAVDA-UHFFFAOYSA-N 3-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C CEAVPXDEPGAVDA-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- LFCUXTYUESPPGC-UHFFFAOYSA-N 4-(phenylmethoxycarbonylamino)bicyclo[2.2.2]octane-1-carboxylic acid Chemical compound C1CC(C(=O)O)(CC2)CCC12NC(=O)OCC1=CC=CC=C1 LFCUXTYUESPPGC-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 1
- AGYWDGVTLKNTBS-UHFFFAOYSA-N 4-bromo-1-chloro-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1Cl AGYWDGVTLKNTBS-UHFFFAOYSA-N 0.000 description 1
- CZGVAISJIQNQEJ-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzaldehyde Chemical compound FC1=CC(Br)=CC(F)=C1C=O CZGVAISJIQNQEJ-UHFFFAOYSA-N 0.000 description 1
- DHGPLNJITGVCSG-UHFFFAOYSA-N 4-bromo-2-chlorobenzaldehyde Chemical compound ClC1=CC(Br)=CC=C1C=O DHGPLNJITGVCSG-UHFFFAOYSA-N 0.000 description 1
- GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
- RCBPVESMGNZMSG-UHFFFAOYSA-N 4-bromo-2-methylbenzaldehyde Chemical compound CC1=CC(Br)=CC=C1C=O RCBPVESMGNZMSG-UHFFFAOYSA-N 0.000 description 1
- LDYVDYZLCRUOTM-UHFFFAOYSA-N 4-bromo-3-chlorobenzaldehyde Chemical compound ClC1=CC(C=O)=CC=C1Br LDYVDYZLCRUOTM-UHFFFAOYSA-N 0.000 description 1
- HKLCOMKRVBQSHA-UHFFFAOYSA-N 4-bromo-3-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1Br HKLCOMKRVBQSHA-UHFFFAOYSA-N 0.000 description 1
- KCDKINCUTSIQAF-UHFFFAOYSA-N 4-bromo-6-chloro-1h-indazole Chemical compound ClC1=CC(Br)=C2C=NNC2=C1 KCDKINCUTSIQAF-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- NJESAXZANHETJV-UHFFFAOYSA-N 4-methylsalicylic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1 NJESAXZANHETJV-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- JBHXSCWBUYDTDR-UHFFFAOYSA-N 5-(chloromethyl)pyridine-3-carbonitrile;hydrochloride Chemical compound Cl.ClCC1=CN=CC(C#N)=C1 JBHXSCWBUYDTDR-UHFFFAOYSA-N 0.000 description 1
- WRZOMWDJOLIVQP-UHFFFAOYSA-N 5-Chloro-ortho-toluidine Chemical compound CC1=CC=C(Cl)C=C1N WRZOMWDJOLIVQP-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- HMURQOFNWZWERT-UHFFFAOYSA-N 5-bromo-3-fluoropyridine-2-carbonitrile Chemical compound FC1=CC(Br)=CN=C1C#N HMURQOFNWZWERT-UHFFFAOYSA-N 0.000 description 1
- QDFJJHGAODFQMN-UHFFFAOYSA-N 5-bromo-3-methoxypyrazin-2-amine Chemical compound COC1=NC(Br)=CN=C1N QDFJJHGAODFQMN-UHFFFAOYSA-N 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ZIOYQUNKXJQXQY-UHFFFAOYSA-N 5-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC=C(O)C=C1C(O)=O ZIOYQUNKXJQXQY-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- XRIHTJYXIHOBDQ-UHFFFAOYSA-N 6-methyl-2-oxo-1h-pyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C(=O)N1 XRIHTJYXIHOBDQ-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 101150078577 Adora2b gene Proteins 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- GPDBIGSFXXKWQR-MGCOHNPYSA-N CC(C)(C)OC(=O)N[C@H]1CC[C@H](C=O)CC1 Chemical compound CC(C)(C)OC(=O)N[C@H]1CC[C@H](C=O)CC1 GPDBIGSFXXKWQR-MGCOHNPYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- NHAYDXCUCXRAMF-MEZFUOHNSA-N Cl.COC(=O)[C@H]1CC[C@H](N)CC1 Chemical compound Cl.COC(=O)[C@H]1CC[C@H](N)CC1 NHAYDXCUCXRAMF-MEZFUOHNSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- RLAHWVDQYNDAGG-UHFFFAOYSA-N Methanetriol Chemical compound OC(O)O RLAHWVDQYNDAGG-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- FOFDIMHVKGYHRU-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide Chemical compound C12=CC=CC=C2OC2=C1N=CN=C2N(CC1)CCN1C(=S)NCC1=CC=C(OCO2)C2=C1 FOFDIMHVKGYHRU-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- YEOHHQAXGGADFI-UHFFFAOYSA-N OB(O)OC=C.CC(C)(O)C(C)(C)O Chemical compound OB(O)OC=C.CC(C)(O)C(C)(C)O YEOHHQAXGGADFI-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 108010064641 ONX 0912 Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229950009447 alisertib Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229950009545 amuvatinib Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 229960003982 apatinib Drugs 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000005239 aroylamino group Chemical group 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 125000005841 biaryl group Chemical group 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- CDCYQPLVFSUEBQ-WCCKRBBISA-N chloromethane (2S)-pyrrolidine-2-carboxylic acid Chemical compound CCl.N1[C@H](C(=O)O)CCC1 CDCYQPLVFSUEBQ-WCCKRBBISA-N 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011244 combinatorial administration Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
- 229950009240 crenolanib Drugs 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229950002966 danusertib Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229950008692 foretinib Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229950004161 ganetespib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical group C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229950002133 iniparib Drugs 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 229950002216 linifanib Drugs 0.000 description 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
- 229950001762 linsitinib Drugs 0.000 description 1
- PKCDDUHJAFVJJB-VLZXCDOPSA-N linsitinib Chemical compound C1[C@](C)(O)C[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-VLZXCDOPSA-N 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- TVIVLENJTXGRAM-UHFFFAOYSA-N methyl 2-(4-aminophenyl)acetate Chemical compound COC(=O)CC1=CC=C(N)C=C1 TVIVLENJTXGRAM-UHFFFAOYSA-N 0.000 description 1
- YPGLGGXSCLUQOR-UHFFFAOYSA-N methyl 2-aminospiro[3.3]heptane-6-carboxylate;hydrochloride Chemical compound Cl.C1C(C(=O)OC)CC11CC(N)C1 YPGLGGXSCLUQOR-UHFFFAOYSA-N 0.000 description 1
- LCACMDQIVIBGNJ-UHFFFAOYSA-N methyl 3-aminobicyclo[1.1.1]pentane-1-carboxylate;hydrochloride Chemical compound Cl.C1C2(N)CC1(C(=O)OC)C2 LCACMDQIVIBGNJ-UHFFFAOYSA-N 0.000 description 1
- BTPCSIFZLLWYTE-UHFFFAOYSA-N methyl 3-aminocyclobutane-1-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1CC(N)C1 BTPCSIFZLLWYTE-UHFFFAOYSA-N 0.000 description 1
- KTFQDZCNPGFKAH-UHFFFAOYSA-N methyl 3-chloro-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(Cl)=C1 KTFQDZCNPGFKAH-UHFFFAOYSA-N 0.000 description 1
- JEJMDUMJSZTJTI-UHFFFAOYSA-N methyl 4,6-dichloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=C1Cl JEJMDUMJSZTJTI-UHFFFAOYSA-N 0.000 description 1
- GIZCKBSSWNIUMZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(CN)C=C1 GIZCKBSSWNIUMZ-UHFFFAOYSA-N 0.000 description 1
- XTZCVWDSGCVDFI-UHFFFAOYSA-N methyl 4-(bromomethyl)-3-chlorobenzoate Chemical compound COC(=O)C1=CC=C(CBr)C(Cl)=C1 XTZCVWDSGCVDFI-UHFFFAOYSA-N 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- BLYKGTCYDJZLFB-UHFFFAOYSA-N methyl 4-oxocyclohexane-1-carboxylate Chemical compound COC(=O)C1CCC(=O)CC1 BLYKGTCYDJZLFB-UHFFFAOYSA-N 0.000 description 1
- QVLONHSXRWCCAE-UHFFFAOYSA-N methyl 6-(hydroxymethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CO)N=C1 QVLONHSXRWCCAE-UHFFFAOYSA-N 0.000 description 1
- UOCWTLBPYROHEF-UHFFFAOYSA-N methyl azetidine-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1CNC1 UOCWTLBPYROHEF-UHFFFAOYSA-N 0.000 description 1
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
- XAYGBKHKBBXDAK-UHFFFAOYSA-N n-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide Chemical compound C=1C=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=CC=1C(=O)N(CC1)CCN1CC1CC1 XAYGBKHKBBXDAK-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229950005750 oprozomib Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950004941 pictilisib Drugs 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229950001626 quizartinib Drugs 0.000 description 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950006764 rigosertib Drugs 0.000 description 1
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- 229950004707 rucaparib Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229960005569 saridegib Drugs 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- KZJPVUDYAMEDRM-UHFFFAOYSA-M silver;2,2,2-trifluoroacetate Chemical compound [Ag+].[O-]C(=O)C(F)(F)F KZJPVUDYAMEDRM-UHFFFAOYSA-M 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010922 spray-dried dispersion Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- IRUJRVAXEALDLJ-UHFFFAOYSA-N tert-butyl 4-[2-(methylamino)ethyl]piperazine-1-carboxylate Chemical compound CNCCN1CCN(C(=O)OC(C)(C)C)CC1 IRUJRVAXEALDLJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FNHPTFKSPUTESA-UHFFFAOYSA-N tert-butyl n-(3-oxocyclobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CC(=O)C1 FNHPTFKSPUTESA-UHFFFAOYSA-N 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005403 thiohaloalkoxy group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- XWNXEWLCHSLQOI-UHFFFAOYSA-K trisodium;triacetate Chemical compound [Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O XWNXEWLCHSLQOI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 229950003081 volasertib Drugs 0.000 description 1
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Description
本発明はPD-L1拮抗薬化合物及びそれを用いて免疫関連症状を治療/予防する方法に関する。
L2、L3は-(CRCRD)p、-(CRCRD)p-NRa-(CRCRD)q-、-(CRCRD)p-O-(CRCRD)q-、-C(O)-から選ばれ、
W1、W2はそれぞれ独立してCRL又はNを表し、
R1はそれぞれ独立して水素、ハロゲン、ニトロ基、シアノ基又は-NRaRb、又は0、1、2、又は3つの置換基によって置換されたC1-C6アルキル基、C3-C6シクロアルキル基、-O(C1-C6アルキル基)、-O(C0-C6アルキレン)(C5-C10アリール基)、-O(C0-C6アルキレン)(5-10員ヘテロアリール基)、-O(C0-C6アルキレン)(C3-C6シクロアルキル基)又は-O(C0-C6アルキレン)(3-6員ヘテロシクロアルキル基) を表し、前記置換基は-ORa、シアノ基、オキソ、ハロゲン、C1-C6アルキル基、-(C1-C6アルキレン)ORa、シアノ基C1-C6アルキル基、C1-C6ハロアルキル基、C3-C8シクロアルキル基、-C(O)Ra、-(C1-C6アルキレン)C(O)Ra、-C(O)ORa、-(C1-C6アルキル基)C(O)ORa、-NRaRb、-(C1-C6アルキレン)NRaRb、-C(O)NRaRb、-SO2Ra、-C(O)NRaSO2Rb、-NRaC(O)Rbから選ばれ、
R2、R3、R4、R5はそれぞれ独立して水素、ハロゲン、ニトロ基、シアノ基、-NRaRb、-SO2Ra、-S(O)Ra、-P(O)RaRb、C1-C6アルキル基、-O(C1-C6アルキル基)、-O(C3-C6シクロアルキル基)、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表し、
Cyは0、1、2、又は3つのR6によって置換されたベンゼン環又は六員ヘテロアリール基を表し、前記六員ヘテロアリール基は所望により1又は2つの窒素原子を含み、前記R6は水素、ハロゲン、ニトロ基、シアノ基、-NRaRb、-SO2Ra、-S(O)Ra又は-P(O)RaRb、又は0、1、2、又は3つの置換基によって置換されたC1-C6アルキル基、C3-C6シクロアルキル基、-O(C1-C6アルキル基)、-O(C0-C6アルキレン)(C5-C10アリール基)、-O(C0-C6アルキレン)(5-10員ヘテロアリール基)、O(C0-C6アルキレン)(C3-C6シクロアルキル基)又は-O(C0-C6アルキレン)(3-6員ヘテロシクロアルキル基) を表し、前記置換基は-ORa、シアノ基、オキソ、ハロゲン、C1-C6アルキル基、-(C1-C6アルキレン)ORa、シアノ基C1-C6アルキル基、C1-C6ハロアルキル基、C3-C8シクロアルキル基、-C(O)Ra、-(C1-C6アルキレン)C(O)Ra、-C(O)ORa、-(C1-C6アルキレン)C(O)ORa、-NRaRb、-(C1-C6アルキレン)NRaRb、-C(O)NRaRb、-SO2Ra、-C(O)NRaSO2Rb、-NRaC(O)Rbから選ばれ、
RLは水素、C1-C6アルキル基、-O(C1-C6アルキル基)、-O(C3-C6シクロアルキル基)、ハロゲン、ニトロ基、シアノ基、-NRaRb、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表し、
T、Aはそれぞれ独立して0、1、2、又は3つの置換基によって置換された-(C1-C6アルキル基)、-(C0-C6アルキレン)-(C3-C12シクロアルキル基)、-(C0-C6アルキレン)-(3-12員ヘテロシクロアルキル基)、-(C0-C6アルキレン)-(C6-C10アリール基)又は-(C0-C6アルキレン)-(5-10員ヘテロアリール基) を表し、前記置換基はシアノ基、オキソ、ハロゲン、C1-C6アルキル基、-(C0-C6アルキレン)ORa、シアノ基C1-C6アルキル基、ハロ(C1-C6アルキル基)、C3-C8シクロアルキル基、-(C0-C6アルキレン)C(O)Ra、-(C0-C6アルキレン)C(O)ORa、-(C0-C6アルケニル)C(O)ORa、(C0-C6アルキレン)NRaRb、-C(O)NRaRb、-NRaSO2Rb、-C(O)NRaSO2Rb、-NRaC(O)Rbから選ばれ、
RA、RBはそれぞれ独立して水素、C1-C6アルキル基、-(C0-C3アルキレン)(C3-C12シクロアルキル基)、-(C0-C3アルキレン)(3-12員ヘテロシクロアルキル基)、ハロ(C1-C6アルキル基)又はハロゲンを表し、または、RAとRBは、それらの共結合した炭素原子と一緒になって3~6員の環を形成し、
RC、RDはそれぞれ独立して水素、C1-C6アルキル基、-(C0-C3アルキレン)(C3-C12シクロアルキル基)、-(C0-C3アルキレン)(3-12員ヘテロシクロアルキル基)、ハロ(C1-C6アルキル基) 又はハロゲンを表し、又はは、RCとRDは、それらの共結合原子と一緒になって3~6員の環を形成し、
Ra、Rbはそれぞれ独立して水素、C1-C6アルキル基、ハロ(C1-C6アルキル基)、-(C0-C6アルキレン)OH、-(C0-C3アルキレン)(C3-C12シクロアルキル基)、-(C0-C3アルキレン)(3-12員ヘテロシクロアルキル基)、-(C0-C3アルキレン)(C6-C10員芳香環)、-(C0-C3アルキレン)(5-10員ヘテロ芳香環) 又はハロ(C1-C6アルキル基) を表し、又は、RaとRbは、それらの共結合原子と一緒になって3~6員の環を形成し、
m、oはそれぞれ独立して0、1又は2を表し、
p、qはそれぞれ独立して0、1、2又は3を表す。
rは0、1、2又は3を表す。
W3はCRM又はNを表し、
RMは水素、C1-C6アルキル基、-O(C1-C6アルキル基)、-O(C3-C6シクロアルキル基)、ハロゲン、ニトロ基、シアノ基、-NRaRb、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基、
rは0、1又は2を表す。
W4はCRN又はNを表し、
RNは水素、C1-C6アルキル基、-O(C1-C6アルキル基)、-O(C3-C6シクロアルキル基)、ハロゲン、ニトロ基、シアノ基、-NRaRb、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表し、
rは0、1又は2を表す。
本発明の化合物で、W3は好ましくはCH又はNを表す。
本発明の化合物で、W4は好ましくはCH又はNを表す。
本発明の化合物で、T、Aはそれぞれ好ましくは独立して
本発明の化合物で、T、Aはそれぞれ好ましくは独立して下記のグループを表す
本発明の化合物において、R5は好ましくは水素、ハロゲン、ニトロ基、シアノ基、C1-C6アルキル基、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表す。
本発明の化合物において、RM、RNはそれぞれ好ましくは独立して水素を表す。
詳細な説明
具体的には、本発明は次の構造の化合物を提供する。
なお、本明細書で特定の構造式を有する「化合物」が言及される場合に、一般に、その立体異性体、ジアステレオマー、エナンチオマー、ラセミ混合物、同位体誘導体、及びその代替的な存在形態としてその薬用塩、溶媒和物、水和物等の形態が含まれる。当業者に周知されるように、化合物の塩、溶媒和物、水和物は化合物の代替的な存在形態であり、特定の条件下で当該化合物に変換される。したがって、本明細書で対象化合物が言及される場合に、一般にその薬用塩が含まれ、その溶媒和物及び水和物が含まれる。
本発明に記載の薬用塩又は薬学的に許容される塩は無機酸又は有機酸によって形成されてもよく、前記「薬用塩」又は「薬学的に許容される塩」とは合理的な医学的判断では、ヒト及び下等動物の組織と接触して使用することに適し、不適切な毒性、刺激性、アレルギー反応等がなく、合理的な利益/リスク比に見合うような塩をいう。本発明の化合物の最終的な分離及び精製の時、前記塩をその場合成してもよいし、下記のように、遊離塩基又は遊離酸と適切な試薬を反応させて前記塩を製造してもよい。例えば、遊離塩基が適切な酸と反応できる。また、本発明の化合物が酸性部分を有する場合に、その適切な薬用塩には、金属塩、例えば、アルカリ金属塩(例えば、ナトリウム塩又はカリウム塩)及びアルカリ土類金属塩(例えば、カルシウム塩又はマグネシウム塩)が含まれる。薬学的に許容される非毒性酸付加塩の例としては、アミノ基が無機酸(例えば、塩酸、臭化水素酸、リン酸、硫酸、過塩素酸)もしくは有機酸(例えば、酢酸、シュウ酸、マレイン酸、酒石酸、クエン酸、コハク酸、マロン酸)と形成した塩、又は従来技術による他の方法、例えば、イオン交換によって形成させた塩が挙げられる。他の薬用塩には、アジピン酸塩、アルギン酸ナトリウム、アスコルビン酸塩、アスパラギン酸塩、ベンゼンスルホン酸塩、安息香酸塩、硫酸水素塩、ホウ酸塩、酪酸塩、樟脳酸塩、カンファースルホン酸塩、クエン酸塩、シクロペンチルプロピオン酸塩、ジグルコン酸塩、ラウリル硫酸塩、エタンスルホン酸塩、ギ酸塩、フマル酸塩、グルコヘプトン酸塩、グリセリンリン酸塩、グルコン酸塩、ヘミ硫酸塩(hernisulfate)、ヘプタン酸、ヘキサン酸塩、ヨウ化水素酸塩、2-ヒドロキシ-エタンスルホン酸塩、ラクトビオン酸塩、乳酸塩、ラウリン酸塩、ラウリル硫酸塩、リンゴ酸塩、マレイン酸塩、マロン酸塩、メタンスルホン酸塩、2-ナフタレンスルホン酸塩、ニコチン酸塩、硝酸塩、オレイン酸塩、シュウ酸塩、パルミチン酸塩、パモ酸塩、ペクチン酸塩、過硫酸塩、3-フェニルプロピオン酸塩、リン酸塩、ピクリン酸塩、ピバル酸塩、プロピオン酸塩、ステアリン酸塩、コハク酸塩、硫酸塩、酒石酸塩、チオシアン酸塩、p-トルエンスルホン酸塩、ウンデカン酸塩、吉草酸塩等が含まれる。代表的なアルカリ金属塩又はアルカリ土類金属塩にはナトリウム塩、リチウム塩、カリウム塩、カルシウム塩、マグネシウム塩等が含まれる。他の薬用塩には、(適切であれば)非毒性のアンモニウム塩、第四アンモニウム塩、対イオンによって形成させたアンモニウムカチオン、例えば、ハロゲン化物、水酸化物、カルボン酸塩、硫酸塩、リン酸塩、硝酸塩、低級アルキルスルホン酸塩、アリールスルホン酸塩が含まれる。
用語「アリール基」は、それ自体で又は例えば、「アラルキル基」、「アラルコキシ基」又は「アリールオキシアルキル基」の一部として、合計で5個ないし12個の環上原子からなる単環、二環又は三環の環系を意味し、ただし前記環系中の少なくとも1つの環は芳香族環であり、且つ前記環系中の各環は3個ないし7個の環上原子を有する。本発明のいくつかの実施形態では、「アリール基」は、フェニル基、ビフェニル基、インダニル基、1-ナフチル基、2-ナフチル基、テトラヒドロナフチル基を含むがこれらに限定されない芳香族環系を意味する。用語「アラルキル基」又は「アリールアルキル基」は芳香族環に接続されたアルキル残基を意味する。非限定的な例として、ベンジル基、フェネチル基等が挙げられる。縮合アリール基はシクロアルキル環又は芳香族環の適切な位置で他の基に接続されたものであってもよい。例えば、環系から引いた破線が、任意の適切な環上原子に結合が接続されてもよいことを意味する。
用語「ヘテロアリール基」は、安定的な3員、4員、5員、6員、又は7員の芳香族単環もしくは芳香族二環、又は7員、8員、9員、10員、11員、12員の芳香族多環式複素環であって、炭素原子及びN、O、Sから独立して選ばれる1、2、3又は4個のヘテロ原子を有する完全に不飽和の又は部分的に不飽和のもので、上記で定義した任意の複素環とベンゼン環が縮合されてなる多環式基を含むものを意味する。窒素及び硫黄ヘテロ原子は所望により酸化されてもよい。窒素原子が置換されてもよいし置換されなくてもよい(即ちN又はNRで、ここでRはH、又は定義がある場合は他の置換基である)。複素環は、安定的な構造にできる任意のヘテロ原子又は炭素原子においてペンダント基に接続されてもよい。得られた化合物が安定的なものである場合に、本明細書に記載の複素環基は炭素又は窒素原子において置換されてもよい。複素環中の窒素原子は所望により四級化されてもよい。なお、複素環でSとO原子の総数が1を超えた場合には、これらのヘテロ原子が互いに隣接しないことが好ましい。複素環でSとO原子の総数が1以下であることが好ましい。用語「複素環」が使用される場合は、芳香族複素環を含むことが意図される。芳香族複素環の例は、アクリジニル基、アゼチジニル基、アゾシニル基、ベンゾイミダゾリル基、ベンゾフリル基、ベンゾチオフリル基、ベンゾチエニル基、ベンゾオキサゾリル基、ベンゾオキサゾリニル基、ベンゾチアゾリル基、ベンゾトリアゾリル基、ベンゾテトラゾリル基、ベンゾイソオキサゾリル基、ベンゾイソチアゾリル基、ベンゾイミダゾリニル基、カルバゾリル基、4aH-カルバゾリル基、カルボリニル基、クロマニル基、クロメニル基、シンノリニル基、デカヒドロキノリニル基、2H,6H-1,5,2-ジチアジニル基、ジヒドロフロ[2,3-b]テトラヒドロフリル基、フリル基、フラザニル基、イミダゾリジニル基、イミダゾリニル基、イミダゾリル基、1H-インダゾリル基、イミダゾピリジル基、インドレニル基(indolenyl)、ジヒドロインドリル基、インダジニル基、インドリル基、3H-インドリル基、イサチノイル基(isatinoyl)、イソベンゾフリル基、イソクロマニル基、イソインダゾリル基、イソジヒドロインドリル基、イソインドリル基、イソキノリニル基、イソチアゾリル基、イソチアゾロピリジル基、イソオキサゾリル基、イソキサゾロピリジル基、メチレンジオキシフェニル基、モルホリニル基、フタラジニル基、オクタヒドロイソキノリニル基、オキサジアゾリル基、1,2,3-オキサジアゾリル基、1,2,4-オキサジアゾリル基、1,2,5-オキサジアゾリル基、1,3,4-オキサジアゾリル基、オキサゾリジニル基、オキサゾリル基、オキサゾピリジル基、オキサゾリジニル基、ペリミジニル基、インドキシル基、ピリミジニル基、フェナントリジニル基、フェナントロリニル基、フェナジニル基、フェノチアジニル基、フェノキサチイニル基、フェノキサジニル基、フタラジニル基、ピペラジニル基、ピペリジニル基、ピペリドニル基、4-ピペリドニル基、ピペロニル基、プテリジニル基、プリニル基、ピラニル基、ピラジニル基、ピラゾリジニル基、ピラゾリニル基、ピラゾロピリジル基、ピラゾリル基、ピリダジニル基、ピリドオキサゾリル基、ピリドイミダゾリル基、ピリドチアゾリル基、ピリジル基、ピリミジニル基、ピロリジニル基、ピロリニル基、2-ピロリドニル基、2H-ピロリル基、ピロリル基、キナゾリニル基、キノリニル基、4H-キノリジジニル基、キノキサリル基、キヌクリジニル基、テトラゾリル基、テトラヒドロフリル基、テトラヒドロイソキノリニル基、テトラヒドロキノリニル基、6H-1,2,5-チアジアジニル基、1,2,3-チアジアゾリル基、1,2,4-チアジアゾリル基、1,2,5-チアジアゾリル基、1,3,4-チアジアゾリル基、チアントレニル基、チアゾリル基、チエニル基、チアゾロピリジル基、チエノチアゾリル基、チエノオキサゾリル基、チエノイミダゾリル基、チエニル基、トリアジニル基、1,2,3-トリアゾリル基、1,2,4-トリアゾリル基、1,2,5-トリアゾリル基、1,3,4-トリアゾリル基、キサンテニル基、キノリニル基、イソキノリニル基、フタラジニル基、キナゾリニル基、インドリル基、イソインドリル基、ジヒドロインドリル基、1H-インダゾリル基、ベンゾイミダゾリル基、1,2,3,4-テトラヒドロキノリニル基、1,2,3,4-テトラヒドロイソキノリニル基、5,6,7,8-テトラヒドロ-キノリニル基、2,3-ジヒドロ-ベンゾフリル基、クロマニル基、1,2,3,4-テトラヒドロ-キノキサリル基、1,2,3,4-テトラヒドロ-キナゾリニル基を含むが、これらに限定されない。用語「ヘテロアリール基」は上記で定義した「アリール基」と単環式「ヘテロアリール基」が形成したビアリール基構造(例えば、-フェニルビピリジル-、-フェニルビピリミジニル、-ピリジルビフェニル、-ピリジルビピリミジニル-、-ピリミジニルビフェニル-)をさらに含んでもよく、本発明は、例えば前記複素環を有する縮合環化合物及びスピロ環化合物をさらに含む。
本明細書で使用される用語「架橋複素環基」は2つ以上の炭素原子が共有されてなる多環式化合物を意味し、当該環はO、N、Sから選ばれた原子を少なくとも1つ含む。二環架橋複素環及び多環架橋複素環に分けられる。
本明細書で使用される用語「薬用」又は「薬学的に許容される」は、合理的な医学的判断では、ヒト及び動物の組織と接触して使用することに適し、過度の毒性、刺激性、アレルギー反応及び/又は他の問題や合併症がなく、合理的な利益/リスク比に見合う化合物、物質、組成物及び/又は剤形を意味する。
本明細書で使用される用語「がん」は、制御できない状態で、しかも特定の条件で転移(拡散)できる細胞の異常な増殖を意味する。がんには、固形腫瘍(例えば、膀胱、腸、脳、胸部、子宮、心臓、腎臓、肺、リンパ組織(リンパ腫)、卵巣、膵臓、他の内分泌器官(例えば、甲状腺)、前立腺、皮膚(黒色腫))又は血液系腫瘍(例えば、非白血性白血病)を含むが、これらに限定されない。
用語「対象」、「被験者」又は「患者」には哺乳動物及び非哺乳動物が含まれる。哺乳動物は、哺乳類(ヒト、ヒト以外の霊長類、例えば、オランウータン、サル)、産業動物(例えば、ウシ、ウマ、ヤギ、ヒツジ、ブタ)、家畜(ウサギ、イヌ)、実験動物(げっ歯類、例えば、ラット、マウス、モルモット等)を含むが、これらに限定されない。非哺乳類動物は、鳥類、魚類等を含むが、これらに限定されない。好ましい一例では、哺乳動物はヒトである。
適切な投与経路は、経口、静脈注射、経直腸、エアゾール剤、非経口投与、眼内投与、肺内投与、経皮投与、経膣投与、耳道内投与、鼻腔投与、局所投与を含むが、これらに限定されない。また、例示的に、非経口投与は、筋肉内注射、皮下注射、静脈注射、髄内注射、心室注射、腹腔内注射、リンパ内注射、鼻腔内注射を含む。
本明細書で使用される用語「薬用担体」は薬用物質、組成物又はビヒクルを意味し、例えば、液体もしくは固体充填剤、希釈剤、賦形剤、各種助剤(例えば、潤滑剤、タルク、ステアリン酸マグネシウム、ステアリン酸カルシウム、ステアリン酸亜鉛もしくはステアリン酸)又は溶媒封入物質であって、対象化合物を担持しながら特定の器官又は身体の部分から他の器官又は身体の部分に輸送するように機能するものを意味する。各担体は製剤の他の成分に適合し、患者に無害であるという意味で「許容され」なければならない。
本発明の医薬組成物における有効成分の実際の用量レベルを調整して、特定の患者に期待される治療応答、組成及び投与方式を効果的に実現でき、且つ患者に毒性がない有効成分の量を得る。
キット/製品包装
ここで、上記の適応症を治療するために使用されるキット/製品包装を説明する。これらのキットは輸送装置、薬品パック又はコンテナーボックスから構成され、コンテナーボックスはいくつかの部分に分割されて、1種以上の容器(例えば、バイアル、試験管等)を収容でき、各容器には前記方法に係る1種の成分が含まれる。適切な容器がボトル、バイアル、注射器、試験管等を含む。容器は使用が許容されるガラス又はプラスチック等の材料から製造される。
一般的なプロセス
市販の試薬をさらに精製することなく使用した。1H-NMRスペクトルは、500MHzでBruker装置で記録された。化学シフト値は、100万分の1、つまりδ値で表された。次の略語は、NMR信号の多重度に使用される。s =シングレット、brs =ブロード、d =ダブレット、t =トリプレット、m =マルチプレット。結合定数は、J値でリストされ、Hzで測定された。 NMRおよび質量スペクトルの結果は、バックグラウンドピークに対して補正された。 クロマトグラフィーとは、100メッシュのシリカゲルを使用して窒素圧下で行うカラムクロマトグラフィー(フラッシュクロマトグラフィー)を指す。 反応をモニタリングするためのTLCとは、特定の移動相とMerckからのシリカゲルF254を固定相として使用して実行されるTLCである。
装置:Thermo U3000、ALLtech ELSD、MSQ、ELSDとMSDを組み合わせたUV検出器(流出比4:1)。カラム:Waters X-Bridge C-18、3.5μm、4.6x50mm。カラム温度:30 oC。 グラジエント[時間(分)/溶媒B in A(%)]:0.00 / 5.0、0.70 / 95、1.40 / 95、1.41 / 5、1.50 / 5。(溶媒A =水中の0.01%トリフルオロ酢酸、溶媒B =アセトニトリル中の0.01%トリフルオロ酢酸)。 UV検出:214/254/280 / 300nm。DAD検出:200-400nm。流量:4mL / min。MS:ESI、100-1500 m / z
分取HPLCは通常、基本的な方法を使用する(アセトニトリルと水の勾配、水中に10 mM炭酸水素アンモニウムを含む)。Thermo U3000 AFC-3000。カラム:Globalsil C-18 12 nm、250 x 20 mm、10 μm、または同等のもの。流量:分離には20mL / min。
化合物INT-1の調製
5-クロロメチル-3-シアノピリジン塩酸塩(3.20 g,17.0 mmol)をN,N-ジメチルホルムアミド(20 ML)に溶解し、氷浴下でN,N-ジイソプロピルエチルアミン (5.48 g, 42.4 mmol) と炭酸カリウム (5.86 g, 42.4 mmol)を加入した。10分間攪拌した後、上記反応液にINT-1c (4.25 g, 14.1 mmol) とヨウ化カリウム (234 mg、1.41 mmol) を加入した。反応液は氷浴下で30分間攪拌した。その後温度を50°Cに上昇して、16時間攪拌した。反応液は氷浴下で冷却し、100 mL水を加入した後固体が析出した。固体を濾過し、水で洗浄し、乾燥して、その後固形粗生成物はシリカゲルカラムクロマトグラフィーで分離して白色の固体INT-1d (5.00 g、収率: 84.9%)を得た。MS (ESI): m/z 417.2 (M+H)+.
化合物INT-1d (5.0 g, 12.0 mmol) をトルエン (10 mL) に溶解し、エチレングリコール(14.9 g, 240 mmol) とp-トルエンスルホン酸(228 mg、1.20 mmol)を加入し、その後オルトギ酸トリメチル (2.55 g, 24.0 mmol) を滴下した。混合物は窒素雰囲気下で80°Cに加熱し16時間攪拌した。反応液は氷浴下で冷却し、飽和炭酸水素ナトリウム水溶液 (50 mL) でクエンチし、水相は酢酸エチルで抽出した (100 mL x 2)。合併有機相は飽和食塩水 (200 mL) で洗浄し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮した。残留物はシリカゲルカラムクロマトグラフィーで分離して白色の固体INT-1e (5.50 g、収率: 99.5%)を得た。MS (ESI): m/z 461.2 (M+H)+.
化合物INT-1e (2.20 g, 4.77 mmol) をテトラヒドロフラン (10 mL) に溶解し、テトラブチルフッ化アンモニウムのテトラヒドロフラン溶液 (1 M, 7.16 mL) を加入し、反応液は30°C条件下で半時間攪拌した。水(30 mL)で希釈し、水相を酢酸エチルで抽出した(50 mL x 2)。合併有機相は飽和食塩水(50 ml)で洗浄し、無水硫酸ナトリウムで乾燥、ろ過し、濃縮した。残留物は酢酸エチルと石油エーテル混合液 (v/v = 3/100, 20 mL) でスラリー化し、濾過して淡黄色の固体INT-1f を得た(1.58 g、収率: 95.5%)。MS (ESI): m/z 347.2 (M+H)+.
化合物INT-1f (1.50 g, 4.33 mmol) をジクロロメタン (30 mL) に溶解し、N,N-ジイソプロピルエチルアミン (1.68 g, 13.0 mmol) を加入し、0°Cと窒素雰囲気下でメタンスルホン酸無水物 (1.51 g, 8.65 mmol) を加入した。その後N,N-ジイソプロピルエチルアミン (1.68 g, 13.0 mmol)と塩酸ジオキサン (4 M, 1.62 mL) のジクロロメタン (10 mL) 混合液を加入した。反応液は25°C条件下で16時間攪拌した。水 (30 mL) で反応をクエンチし、水相はジクロロメタンで抽出した (50 mL x 2)。合併有機相は飽和食塩水 (50 mL) で洗浄し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮した。残留物はシリカゲルカラムクロマトグラフィーで分離して淡黄色の固体INT-1g (1.40 g、収率: 88.6%)を得た。MS (ESI): m/z 365.2 (M+H)+.
化合物INT-1g (1.36 g, 3.72 mmol)、4-ブロモ-1H-インダゾール (734 mg、3.72 mmol)と炭酸カリウム (1.03 g, 7.45 mmol)をN,N-ジメチルホルムアミド (10 mL)に溶解した。混合物は50°C下で16時間攪拌した。反応液は氷浴下で冷却し、100 mL水を加入して固体が析出した、濾過し、水で洗浄し、乾燥した。得られた固形粗生成物はシリカゲルカラムクロマトグラフィーで分離して淡黄色の固体INT-1h (1.08 g、収率: 55.2%)を得た。1H NMR (500 MHz, DMSO-d6) δ 8.96 (d, J = 2.0 Hz, 1H), 8.82 (s, 1H), 8.27 (s, 1H), 8.05 (s, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.45 (s, 1H), 7.40 (d, J = 7.5 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 6.91 (s, 1H), 6.04 (s, 1H), 5.71 (s, 2H), 5.16 (s, 2H), 4.04 - 4.01 (m, 2H), 3.97 - 3.89 (m, 2H); MS (ESI): m/z 525.0 (M+H)+.
化合物INT-1h (1.00 g, 1.90 mmol)をテトラヒドロフラン (20 mL)に溶解し、塩酸 (4.0 Mの水溶液, 5.0 mL)を加入した。反応液は30°C条件下で1時間攪拌した。その後用飽和炭酸水素ナトリウム水溶液で中和した。水相は酢酸エチルで抽出した (50 mL x 2)。合併有機相は飽和食塩水 (100 mL) で洗浄し無水硫酸ナトリウムで乾燥し、濾過し、濃縮して、淡黄色の固体INT-1iを得た (900 mg、収率: 98.2%)。MS (ESI): m/z 481.0 (M+H)+.
化合物INT-1i (840 mg、1.74 mmol) をN,N-ジメチルホルムアミド (5 mL) に溶解し、O-tert-ブチル-L-セリン-t-ブチル (418 mg、1.92 mmol)と酢酸 (209 mg、3.48 mmol)を加入し、反応液は30°C下で1時間攪拌した。その後反応液にトリアセトキシ水素化ホウ素ナトリウム (1.48 g, 6.96 mmol) を加入し、反応は30°C下で1時間攪拌した。その後水 (50 mL) を加入しクエンチして、水相は酢酸エチルで抽出した (50 mL x 2)。合併有機相は飽和食塩水 (50 mL) で洗浄し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮した。残留物はシリカゲルカラムクロマトグラフィーで分離して淡黄色の固体INT-1j (720 mg、収率: 60.5%)を得た。MS (ESI): m/z 682.1 (M+H)+.
中間体INT-1j (1.00 g, 1.46 mmol)、ビホウ酸ピナオール (558 mg、2.20 mmol)、酢酸カリウム (431 mg、4.39 mmol)とPd(dppf)Cl2(107 mg、0.15 mmol) をジオキサン (15 mL) に溶解した。反応液は窒素雰囲気下で90°Cに加熱し一晩攪拌した。反応液は室温に冷却して、酢酸エチル (100 mL) で希釈し、珪藻土で濾過し、そして100 mL酢酸エチルで洗浄して得られた濾液を濃縮した。残留物はシリカゲルカラムクロマトグラフィーで分離して (ジクロロメタン/メタノール、v/v = 20/1)淡黄色の固体INT-1 (600 mg、収率: 56.1%)を得た。MS (ESI): m/z 730.7 (M+H)+.
化合物INT-2の調製
化合物INT-2a (1.0 g, 4.09 mmol) をエタノール (20 mL) に溶解し、80%ヒドラジン水和物(512 mg、8.19 mmol)を加入した。反応液は85°Cに加熱して2時間攪拌した。反応は室温に冷却した後、得られた沈殿物を濾過で取り除いた。濾液を濃縮した後ジクロロメタン (50 mL) を加入し、濾過で得られた濾液をさらに真空濃縮した後黄色油性液体INT-2を得た (430 mg、収率: 92.0%)。1H NMR (500 MHz, DMSO-d6) δ 7.65 (s, 1H), 3.43 - 3.37 (m, 1H), 2.47 - 2.42 (m, 2H), 2.12 - 2.04 (m, 2H), 2.03 - 1.96 (m, 1H), 1.66 - 1.60 (m, 1H), 1.58 (s, 2H).
化合物INT-3の調製
化合物INT-3b (1.41 g, 3.58 mmol) をジクロロメタン (15 mL) に溶解し、順にトリエチルアミン (725 mg、7.16 mmol)と二炭酸ジ-tert-ブチル(860 mg、3.94 mmol)を加入した。反応液は室温下で2時間攪拌した。そして200 mLジクロロメタンで希釈した。得られた有機相は順に水 (100 mL)と飽和食塩水 (100 mL) で洗浄し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮した。残留物はシリカゲルカラムクロマトグラフィーで分離して (ジクロロメタン/メタノール、v/v = 20/1)白色の固体INT-3 (1.55 g、収率: 87.6%)を得た。1H NMR (500 MHz, DMSO-d6) δ 7.78 (dd, J = 7.8 Hz, 1H), 7.69 (s, 1H), 7.44 - 7.25 (m, 6H), 4.53 - 4.39 (m, 2H), 3.80 - 3.70 (m, 1H), 3.26 - 3.10 (m, 2H), 2.17 - 1.99 (m, 3H), 1.76 - 1.66 (m, 1H), 1.38 (s, 9H); MS (ESI): m/z 493.3 (M+H)+.
化合物INT-4の調製
化合物INT-5の調製
化合物INT-6の調製
化合物INT-6aから、化合物INT-3の合成方法を参照し、化合物INT-6を得た。1H NMR (500 MHz, DMSO-d6) δ 7.78 (d, J = 8.0 Hz, 1H), 7.70 (s, 1H), 7.42 - 7.38 (m, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.11 - 7.03 (m, 1H), 7.02 - 7.00 (m, 1H), 6.98 - 6.93 (m, 1H), 4.47-4.34 (m, 2H), 3.81 (s, 3H), 3.77 - 3.71 (m, 1H), 3.26 - 3.17 (m, 2H), 2.18 - 2.10 (m, 1H), 2.09 - 2.00 (m, 2H), 1.74 - 1.64 (m, 1H), 1.47 - 1.26 (m, 9H). MS (ESI): m/z 523.2 (M+H)+.
化合物INT-7の調製
化合物INT-7a (96.4 mg、0.18 mmol) と化合物INT-3 (75.0 mg、0.15 mmol)をジオキサンと水 (11 mL、v/v=10/1) の混合溶媒に溶解し、炭酸カリウム (63.0 mg、0.46 mmol)とPd(dppf)Cl2 (11.1 mg、0.015 mmol) を加入し、混合物は窒素雰囲気下で80℃に加熱して3時間攪拌した。その後水 (50 mL) で反応をクエンチし、水相酢酸エチルで抽出した (50 mL x 2)。合併有機相は飽和食塩水(50 ML)で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過、濃縮した。残留物は分取薄層クロマトグラフィー(ジクロロメタン/メタノール、v/v = 95/5) で分離して淡黄色の固体INT-7 (120 mg、収率: 96.9%)を得た。MS (ESI): m/z 815.2 (M+H)+.
化合物INT-8の調製
化合物INT-8bから、化合物INT-7の合成を参照し、化合物INT-8cと化合物INT-8を得た。これらのスペクトル情報は以下のとおりである。
INT-8: MS (ESI): m/z 713.5 (M+H)+.
化合物INT-9の調製
化合物INT-10の調製
化合物INT-10aと6-クロロ-2-メトキシ基-3-ピリジンホルムアルデヒドから、化合物INT-3aの合成方法を参照し、化合物INT-10bを得た。MS (ESI): m/z 262.0 (M-H)-.
化合物INT-10b (500 mg、1.90 mmol) を無水ジクロロメタン (10 mL) 中に溶解し、N,N-ジイソプロピルエチルアミン (490 mg、3.80 mmol)を加入して、氷浴で0°Cに冷却した。その後、ゆっくりとトリフルオロメタンスルホン酸無水物 (804 mg、2.85 mmol) を滴下した。反応液を徐々に室温に上げて、続いて2時間攪拌した。50 mL飽和塩化アンモニウム水溶液で反応をクエンチし、水相は酢酸エチルで抽出した (30 mL x 2)。合併有機相は50 mL飽和食塩水で洗し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮した。残留物はシリカゲルカラムクロマトグラフィーで分離してオレンジ油状物INT-10 (482 mg、収率: 64.2%)を得た。MS (ESI): m/z 396.2 (M+H)+.
化合物INT-11の調製
化合物INT-12の調製
化合物INT-13の調製
化合物INT-14の調製
化合物INT-15の調製
化合物INT-15b: 1H NMR (500 MHz, Chloroform-d) δ 10.42 (s, 1H), 6.76 (s, 2H), 3.90 (s, 6H).
化合物INT-15aから、化合物INT-6の合成方法を参照し、化合物INT-15を得た。1H NMR (500 MHz, DMSO-d6) δ 7.83 (d, J = 8.0 Hz, 1H), 7.71 (s, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 6.90 - 6.86 (m, 2H), 4.54 - 4.50 (m, 2H), 3.84 (s, 3H), 3.77 - 3.73 (m, 1H), 3.17 (d, J = 5.3 Hz, 2H), 2.12 - 2.02 (m, 3H), 1.71 - 1.65 (m, 1H), 1.40 - 1.32 (m, 9H); MS (ESI): m/z 541.5 (M+H)+.
化合物INT-16の調製
化合物INT-17の調製
化合物INT-17aから、化合物INT-13aの合成方法を参照し、無色油状物INT-17bを得た。
化合物INT-17cから、化合物INT-2の合成方法を参考して、淡黄色油状物INT-17を得た。1H NMR (500 MHz, DMSO-d6) δ 7.34 (s, 1H), 3.22 - 3.06 (m, 1H), 2.59 - 2.42 (m, 2H), 2.18 - 1.98 (m, 2H), 1.75 (brs, 2H), 1.64 - 1.50 (m, 2H), 1.37 - 1.18 (m, 2H)。
化合物INT-18aから、化合物INT-1の最後のステップSuzukiホウ素エステル化反応を参照し、化合物INT-18を得た。1H NMR (500 MHz, DMSO-d6) δ 10.31 (s, 1H), 7.68 - 7.64 (m, 1H), 7.55 - 7.51 (m, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.05 (s, 1H), 6.97 - 6.89 (m, 1H), 3.93 (s, 3H), 1.31 (s, 12H); MS (ESI): m/z 391.7 (M+H)+.
実施例化合物の合成
実施例1
化合物1a (20 mg,0.022 mmol)をジクロロメタン(2 mL)に溶解し、トリフルオロ酢酸(2 mL)を加えた。反応液を25oC条件下で6時間攪拌した。反応液を濃縮した後、残留物を分取高速液体クロマトグラフィーで精製して白色の固体1(6.5 mg、収率:37.4%)を得た。1H NMR (500 MHz, DMSO-d6) δ 8.95 (s, 1H), 8.84 (s, 1H), 8.33 (s, 1H), 7.87 (s, 1H), 7.72 - 7.67 (m, 1H), 7.55 - 7.45 (m, 7H), 7.40 (d, J = 8.0 Hz, 2H), 7.18 - 7.15 (m, 1H), 6.83 (s, 1H), 5.74 - 5.69 (m, 2H), 5.11 - 5.05 (m, 2H), 4.24 - 4.18 (m, 1H), 3.93 (d, J = 14.5 Hz, 1H), 3.85 (d, J = 14.5 Hz, 1H), 3.65 (d, J = 13.0 Hz, 1H), 3.61 - 3.55 (m, 2H), 3.12 - 3.07 (m, 1H), 2.72 - 2.68 (m, 1H), 2.65 - 2.58 (m, 2H), 2.38 - 2.32 (m, 2H), 2.05 - 1.97 (m, 1H), 1.59 - 1.52 (m, 1H); MS (ESI): m/z 777.8 (M+H)+.
実施例2
実施例3
化合物3aとモルホリンから、化合物INT-3b合成過程における還元的アミノ化ステップを参照し、化合物3bを得た。MS (ESI): m/z 889.9 (M+H)+.
化合物3bから、化合物1合成中の最後のステップ脱Boc保護ステップを参照し、化合物3を得た。1H NMR (500 MHz, DMSO-d6) δ 8.95 (s, 1H), 8.84 (s, 1H), 8.33 (s, 1H), 7.86 (s, 1H), 7.72-7.67 (m, 1H), 7.56-7.45 (m, 7H), 7.41 (d, J = 7.5 Hz, 2H), 7.17 (d, J = 7.0 Hz, 1H), 6.83 (s, 1H), 5.72 (s, 2H), 5.13 - 5.05 (m, 2H), 3.92 (d, J = 14.0 Hz, 1H), 3.85 (d, J = 14.0 Hz, 1H), 3.63-3.56 (m, 6H), 3.52 (s, 2H), 3.13-3.06 (m, 1H), 2.40 (s, 4H); MS (ESI): m/z 777.6 (M+H)+.
実施例4
実施例5
実施例6
氷浴条件下で、化合物6a (207 mg、0.58 mmol) の溶けたテトラヒドロフラン (5 mL) 溶液中に順にN,N-ジイソプロピルエチルアミン (226 mg、1.75 mmol)とメタンスルホン酸無水物 (203 mg、1.17 mmol) を加入した。反応液は氷浴条件下で半時間攪拌した後、25oCに温度を上げた。同じ温度下で続いて2時間攪拌した。反応液に水 (20 mL) を加入し希釈して、水相はジクロロメタン (20 mL x 2) で抽出した。合併有機相は無水硫酸ナトリウムで乾燥し、濾過し、濃縮して化合物6bを得た。氷浴条件と窒素雰囲気下で、 (R)-(-)-3-ヒドロキシテトラヒドロフラン (103 mg、1.17 mmol) の溶けたテトラヒドロフラン (5 mL) に水素化ナトリウム (60% w/w灯油で、46.8 mg) を加入した。反応液は氷浴条件下で半時間攪拌した。その後上記得られた化合物6bを加入した。得られた反応液を50oCに温度を上げて、一晩攪拌した。室温に冷却した後、反応液は水 (20 mL) でクエンチした。水相は酢酸エチル (20 mL x 2) で抽出した。合併有機相は飽和食塩水 (30 mL) で洗浄し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮した。残留物は分取薄層クロマトグラフィーで (ジクロロメタン/メタノール、v/v = 15/1) 分離して黄色油状物6cを得た (110 mg、収率: 44.4%)。MS (ESI): m/z 424.3 (M+H)+.
化合物INT-1と化合物6cから、化合物1の合成を参照し、化合物6を得た。1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J = 2.0 Hz, 1H), 8.84 (d, J = 2.0 Hz, 1H), 8.34 - 8.32 (m, 1H), 7.86 (s, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.55 - 7.45 (m, 7H), 7.40 (d, J = 8.0 Hz, 2H), 7.20 - 7.15 (m, 1H), 6.81 (s, 1H), 5.72 (s, 2H), 5.12 - 5.05 (m, 2H), 4.12 - 4.08 (m, 1H), 3.89 - 3.77 (m, 2H), 3.73 - 3.68 (m, 1H), 3.67 - 3.62 (m, 3H), 3.57 (s, 2H), 3.55 - 3.48 (m, 4H), 3.02 - 2.94 (m, 1H), 2.55 (t, J = 6.0 Hz, 2H), 2.20 (s, 3H), 1.94 - 1.83 (m, 2H); MS (ESI): m/z 835.7 (M+H)+.
実施例7
化合物INT-1と化合物7aから、化合物1の合成を参照し、化合物7を得た。1H NMR (500 MHz, DMSO-d6) δ 8.99 - 8.90 (m, 1H), 8.90 - 8.79 (m, 1H), 8.32 (s, 1H), 7.86 (s, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.57 - 7.43 (m, 9H), 7.17 (d, J = 7.0 Hz, 1H), 6.83 (s, 1H), 5.72 (s, 2H), 5.15 - 5.05 (m, 2H), 3.97 - 3.91 (m, 1H), 3.89 - 3.83 (m, 1H), 3.78 (s, 2H), 3.68 - 3.52 (m, 3H), 3.18 - 3.10 (m, 1H), 2.73 - 2.63 (m, 5H), 2.33 - 2.22 (m, 1H), 2.18 - 2.08 (m, 1H), 2.06 - 1.98 (m, 1H), 1.87 - 1.77 (m, 1H); MS (ESI): m/z 818.6 (M+H)+.
実施例8
実施例9
化合物9aから、化合物INT-7aの合成を参照し、化合物9bを得た。MS (ESI): m/z 840.6 (M+H)+.
化合物9bと2-ブロモ-5-アルデヒド基ピリジンから、化合物INT-7合成中の最後のステップSuzuki反応を参照し、化合物9cを得た。MS (ESI): m/z 819.4 (M+H)+.
化合物9cと化合物INT-2から、化合物INT-3b合成中の還元的アミノ化ステップを参照し、化合物9dを得た。MS (ESI): m/z 917.8 (M+H)+.
化合物9dから、化合物1合成中の最後のステップ脱Bocステップを参照し、化合物9を得た。1H NMR (500 MHz, DMSO-d6) δ 8.96 (d, J = 2.0 Hz, 1H), 8.84 (d, J = 2.0 Hz, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.33 (s, 1H), 7.92 - 7.83 (m, 2H), 7.75 - 7.66 (m, 3H), 7.65 - 7.55 (m, 3H), 7.52 - 7.44 (m, 1H), 7.21 - 7.14 (m, 1H), 6.86 (s, 1H), 5.73 (s, 2H), 5.15 - 5.05 (m, 2H), 3.99 - 3.73 (m, 4H), 3.69 - 3.55 (m, 3H), 3.21 - 3.15 (m, 1H), 2.58 - 2.52 (m, 2H), 2.18 - 2.03 (m, 3H), 1.75 - 1.64 (m, 1H); MS (ESI): m/z 805.8 (M+H)+.
実施例10
実施例11
実施例12
化合物12a、化合物INT-2と化合物INT-1から、化合物INT-3と化合物1の合成を参照し、化合物12を得た。1H NMR (500 MHz, DMSO-d6) δ 8.93 (d, J = 2.0 Hz, 1H), 8.84 (d, J = 2.0 Hz, 1H), 8.34 - 8.32 (m, 1H), 8.02 (d, J = 2.5 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.64 - 7.57 (m, 4H), 7.53 (s, 1H), 7.51 - 7.42 (m, 4H), 7.30 - 7.26 (m, 1H), 6.85 (s, 1H), 5.72 (s, 2H), 5.15 - 5.07 (m, 2H), 3.90 (d, J = 14.5 Hz, 1H), 3.85 - 3.72 (m, 3H), 3.65 - 3.60 (m, 1H), 3.56 (d, J = 5.5 Hz, 2H), 3.07 - 2.99 (m, 1H), 2.54 - 2.52 (m, 2H), 2.14 - 2.05 (m, 3H), 1.73 - 1.64 (m, 1H); MS (ESI): m/z 788.3 (M+H)+.
実施例13
化合物13a、化合物INT-2と化合物INT-1から、化合物INT-3と化合物1の合成を参照し、化合物13を得た。1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J = 2.0 Hz, 1H), 8.81 (d, J = 2.0 Hz, 1H), 8.31 - 8.29 (m, 1H), 8.07 (d, J = 2.5 Hz, 1H), 7.93-7.87 (m, 1H), 7.80 - 7.72 (m, 2H), 7.70 - 7.63 (m, 4H), 7.56 - 7.45 (m, 4H), 7.37 - 7.33 (m, 1H), 6.70 (s, 1H), 5.78 - 5.73 (m, 2H), 5.06 - 4.99 (m, 2H), 3.90 (d, J = 15.0 Hz, 1H), 3.84 - 3.75 (m, 3H), 3.71 (d, J = 15.0 Hz, 1H), 3.66 - 3.61 (m, 1H), 3.58 - 3.54 (m, 1H), 3.09 - 3.02 (m, 1H), 2.56 - 2.53 (m, 2H), 2.14 - 2.05 (m, 3H), 1.73 - 1.65 (m, 1H); MS (ESI): m/z 795.7 (M+H)+.
実施例14
化合物14a、化合物INT-2と化合物INT-1から、化合物INT-3と化合物1の合成を参照し、化合物14を得た。1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J = 2.0 Hz, 1H), 8.83 (d, J = 2.0 Hz, 1H), 8.32 - 8.30 (m, 1H), 8.21 - 8.18 (m, 1H), 7.96 - 7.94 (m, 1H), 7.76 - 7.71 (m, 4H), 7.69 - 7.62 (m, 3H), 7.55 (s, 1H), 7.51 - 7.44 (m, 3H), 7.38 (d, J = 7.0 Hz, 1H), 6.83 (s, 1H), 5.76 - 5.70 (m, 2H), 5.16 - 5.08 (m, 2H), 3.94 (d, J = 14.0 Hz, 1H), 3.87 (d, J = 14.0 Hz, 1H), 3.79 (d, J = 14.0 Hz, 1H), 3.75 (d, J = 14.0 Hz, 1H), 3.66 - 3.61 (m, 2H), 3.61 - 3.55 (m, 1H), 3.15 - 3.12 (m, 1H), 2.54 - 2.52 (m, 2H), 2.13 - 2.04 (m, 3H), 1.72 - 1.64 (m, 1H); MS (ESI): m/z 770.7 (M+H)+.
実施例15
将4-ホルミルフェニルホウ酸ピナロール (439 mg、1.89 mmol) と化合物15a (500 mg、1.58 mmol) をジオキサンと水 (10 mL、v/v=4/1) の混合溶媒中に溶解し、炭酸水素ナトリウム (397 mg、4.73 mmol)とPd(dppf)Cl2(58 mg、0.079 mmol) を加入した。反応液は窒素雰囲気下で80℃に加熱して3時間攪拌した。水 (50 mL) で反応をクエンチし、水相は酢酸エチルで抽出した (50 mL x 2)。合併有機相は飽和食塩水 (100 mL) で洗浄し、無水硫酸ナトリウムで乾燥し、濾過し、濃縮した。残留物はシリカゲルカラムクロマトグラフィーで分離して (石油エーテル/酢酸エチル、v/v = 10/1)黄色油状物15b (271 mg、収率: 58.2%)を得た。
実施例16
4-ホルミルフェニルホウ酸ピナロールと化合物16aから、化合物INT-3aの合成を参照し、化合物16bを得た。
化合物16c、化合物INT-2と化合物INT-1から、化合物INT-3と化合物1の合成を参照し、化合物16を得た。1H NMR (500 MHz, DMSO-d6) δ 8.98 - 8.88 (m, 1H), 8.85 - 8.77 (m, 1H), 8.32 - 8.23 (m, 1H), 7.81 (s, 1H), 7.67 - 7.63 (m, 2H), 7.53 (s, 1H), 7.47 - 7.42 (m, 3H), 7.42 - 7.39 (m, 2H), 7.27 - 7.21 (m, 2H), 7.14 - 7.09 (m, 1H), 6.82 (s, 1H), 5.69 (s, 2H), 5.11 - 5.04 (m, 2H), 3.95 - 3.82 (m, 2H), 3.82 - 3.75 (m, 2H), 3.66 - 3.61 (m, 2H), 3.59 - 3.55 (m, 1H), 3.17 - 3.13 (m, 1H), 2.62 - 2.56 (m, 2H), 2.14 - 2.10 (m, 1H), 2.08 (s, 3H), 2.08 - 2.04 (m, 1H), 2.02 - 1.92 (m, 1H), 1.74 - 1.64 (m, 1H); MS (ESI): m/z 818.5 (M+H)+.
実施例17
実施例18
化合物18aと1,3-ジブロモ-2-トルエンから、化合物INT-3aの合成を参照し、化合物18bを得た。MS (ESI): m/z 311.0 (M+H)+.
化合物18bから、化合物6bの合成を参照し、化合物18cを得た。MS (ESI): m/z 389.0 (M+H)+.
50oC条件下で、化合物18c (290 mg、0.74 mmol)、(R)-3-ヒドロキシピロリジン塩酸塩 (138 mg、1.12 mmol)と炭酸セシウム (727 mg、2.23 mmol) の溶けたアセトニトリル (10 mL) 溶液を16時間攪拌した。水 (30 mL) で反応をクエンチし、水相は酢酸エチルで抽出した (30 mL x 2)。有機相を合併し、飽和食塩水(50 ML)で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過、濃縮した。残留物はシリカゲルカラムクロマトグラフィー(ジクロロメタン/メタノール、v/v = 10/1) で分離して黄色油状物18d (140 mg、収率: 49.0%)を得た。MS (ESI): m/z 380.2 (M+H)+.
化合物18dと化合物INT-1から、化合物1の合成を参照し、化合物18を得た。1H NMR (500 MHz, DMSO-d6) δ 8.93 (d, J = 2.0 Hz, 1H), 8.83 (d, J = 2.0 Hz, 1H), 8.33 - 8.31 (m, 1H), 7.86 (s, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.53 - 7.51 (m, 2H), 7.48 - 7.45 (m, 2H), 7.44 - 7.41 (m, 2H), 7.34 - 7.32 (m, 3H), 7.16 (d, J = 7.0 Hz, 1H), 6.79 (s, 1H), 5.71 (s, 2H), 5.08 (d, J = 3.0 Hz, 2H), 4.20 - 4.18 (m, 1H), 3.86 - 3.81 (m, 2H), 3.53 - 3.51 (m, 2H), 2.97 (t, J = 6.0 Hz, 1H), 2.80 - 2.76 (m, 4H), 2.68 - 2.63 (m, 4H), 2.00 - 1.96 (m, 1H), 1.57 - 1.53 (m, 1H); MS (ESI): m/z 791.5 (M+H)+.
実施例19
実施例20
化合物20aから、化合物16cの合成を参照し、臭化亜銅を塩化亜銅に置換し、化合物20bを得た。1H NMR (500 MHz, DMSO-d6) δ 8.00 (s, 2H).
化合物20bから、化合物12の合成を参照し、化合物20を得た。1H NMR (500 MHz, DMSO-d6) δ 8.95 - 8.88 (m, 1H), 8.83 - 8.76 (m, 1H), 8.32 - 8.23 (m, 1H), 7.90 (s, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.68 - 7.64 (m, 1H), 7.61 - 7.58 (m, 1H), 7.56 - 7.41 (m, 7H), 7.21 - 7.14 (m, 1H), 6.79 - 6.66 (m, 1H), 5.70 (s, 2H), 5.13 - 5.01 (m, 2H), 3.83 - 3.70 (m, 4H), 3.61 (t, J = 6.5 Hz, 1H), 3.51 - 3.47 (m, 1H), 3.44 - 3.41 (m, 1H), 2.86 (s, 1H), 2.53 - 2.52 (m, 2H), 2.16 - 2.00 (m, 3H), 1.73 - 1.63 (m, 1H); MS (ESI): m/z 838.3 (M+H)+.
実施例21
25oC条件と窒素雰囲気下で、亜硝酸tert-ブチル (3.91 g, 33.4 mmol) をゆっくりと化合物21a (4.00 g, 13.4 mmol) の溶けたエタノール (30 mL) 溶液に滴下した。反応液は50度条件下で2時間攪拌した。反応液を冷却した後濃縮し、得られた残留物はシリカゲルカラムクロマトグラフィーで分離して白色の固体21b (2.1 g、収率: 55.3%)を得た。1H NMR (500 MHz, Chloroform-d) δ 7.41 (s, 2H), 2.29 (s, 3H).
化合物21bから、化合物12の合成を参照し、化合物21を得た。1H NMR (500 MHz, DMSO-d6) δ 8.93 (d, J = 2.0 Hz, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.31 - 8.29 (m, 1H), 7.84 (s, 1H), 7.72 - 7.63 (m, 2H), 7.53 (s, 1H), 7.48 - 7.39 (m, 5H), 7.33 - 7.25 (m, 2H), 7.13 (d, J = 7.0 Hz, 1H), 6.82 (s, 1H), 5.70 (s, 2H), 5.14 - 5.04 (m, 2H), 3.93 (d, J = 14.5 Hz, 1H), 3.85 (d, J = 14.5 Hz, 1H), 3.80 - 3.73 (m, 2H), 3.67 - 3.54 (m, 3H), 3.14 (t, J = 5.5 Hz, 1H), 2.54 - 2.53 (m, 2H), 2.38 (s, 3H), 2.12 - 2.04 (m, 3H), 1.72 - 1.64 (m, 1H); MS (ESI): m/z 818.8 (M+H)+.
実施例22
実施例23
実施例24
実施例25
実施例26
化合物26bと化合物INT-3から、化合物1の合成を参照し、化合物26を得た。1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J = 2.0 Hz, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.27 (s, 1H), 7.87 (s, 1H), 7.72 - 7.68 (m, 2H), 7.57 - 7.43 (m, 9H), 7.17 (d, J = 7.0 Hz, 1H), 6.80 (s, 1H), 5.71 (s, 2H), 5.09 (s, 2H), 3.82 - 3.69 (m, 6H), 3.66 - 3.58 (m, 2H), 2.55 (d, J = 6.0 Hz, 2H), 2.28 (s, 3H), 2.14 - 2.07 (m, 3H), 1.74 - 1.66 (m, 1H); MS (ESI): m/z 818.8 (M+H)+.
実施例27
25oC条件下で、化合物27a (45 mg、0.054 mmol) の溶けたN’N-ジメチルホルムアミド (2 mL) に (R)-3-ヒドロキシピロリジン塩酸塩 (21 mg、0.14 mmol)とN,N-ジイソプロピルエチルアミン (70 mg、0.54 mmol) を加入した。得られた反応液は同じ温度下で一時間攪拌した。その後三酢酸水素化ホウ素ナトリウム (58 mg、0.27 mmol) を加入し、反応液はさらに25oC条件下で16時間攪拌した。反応液に水 (20 mL)を加入し、酢酸エチル (15 mL x 2) で抽出した。有機相を濃縮し、残留物は分取高速液体色譜カラムクロマトグラフィー純化して白色の固体27(10 mg,収率: 22.6%)を得た。1H NMR (500 MHz, DMSO-d6) δ 8.93 (d, J = 2.0 Hz, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.26 - 8.24 (m, 1H), 7.85 (s, 1H), 7.71 - 7.65 (m, 2H), 7.52 - 7.40 (m, 9H), 7.15 (d, J = 6.9 Hz, 1H), 6.80 (s, 1H), 5.69 (s, 2H), 5.07 (s, 2H), 3.77 (d, J = 12.5 Hz, 1H), 3.74 (d, J = 12.5 Hz, 1H), 3.62 - 3.56 (m, 3H), 2.92 - 2.86 (m, 1H), 2.69 - 2.61 (m, 2H), 2.54 - 2.52 (m, 4H), 2.11 - 2.05 (m, 3H), 1.95 - 1.90 (m, 2H), 1.70 - 1.64 (m, 1H); MS (ESI): m/z 814.8 (M+H)+.
実施例28
実施例29
実施例30
実施例31
実施例32
実施例33
25oC条件下で、化合物33a (90 mg、0.11 mmol) の溶けたメタノールと水 (9 mL、v/v=8/1) の混合溶液に水酸化リチウム(10 mg、0.42 mmol) を加入した。反応液は同じ温度下で一時間攪拌した。反応液を濃縮した後飽和塩化アンモニウムで希釈し、水相は酢酸エチル (10 mL x 2) で抽出した。合併有機相を濃縮した。残留物をジクロロメタンとトリフルオロ酢酸の混合溶液 (4 mL、v/v=3/1) に溶解し、25oC条件下でさらに2時間反応した。反応液を濃縮した後、残留物は分取高速液体クロマトグラフィーで純化してを白色の固体33(10.3 mg,収率: 23.5%)得た。1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.69 (s, 1H), 7.55 - 7.50 (m, 2H), 7.49 - 7.43 (m, 6H), 7.37 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.68 (s, 1H), 5.73 (s, 2H), 3.83 - 3.74 (m, 2H), 3.67 - 3.62 (m, 1H), 3.58 (s, 3H), 3.56 - 3.48 (m, 2H), 2.95 - 2.88 (m, 1H), 2.68 - 2.64 (m, 2H), 2.59 - 2.54 (m, 2H), 2.54 - 2.51 (m, 1H), 2.15 - 2.06 (m, 3H), 1.98 - 1.90 (m, 2H), 1.74 - 1.66 (m, 1H); MS (ESI): m/z 712.7 (M+H)+.
実施例34
化合物34aと化合物INT-8から、化合物33の合成を参照し、化合物34を得た。1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.55 - 7.43 (m, 8H), 7.37 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.67 (s, 1H), 5.73 (s, 2H), 3.81 - 3.73 (m, 2H), 3.66 - 3.61 (m, 1H), 3.58 (s, 3H), 3.56 - 3.47 (m, 2H), 2.92 - 2.86 (m, 1H), 2.69 - 2.62 (m, 2H), 2.56 - 2.53 (m, 2H), 2.49 - 2.46 (m, 1H), 2.14 - 2.07 (m, 3H), 1.96 - 1.90 (m, 2H), 1.74 - 1.66 (m, 1H); MS (ESI): m/z 712.7 (M+H)+.
実施例35
化合物35aと化合物INT-8から、化合物33の合成を参照し、化合物35を得た。1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.55 - 7.42 (m, 8H), 7.39 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.68 (s, 1H), 5.73 (s, 2H), 3.80 - 3.73 (m, 2H), 3.65 - 3.61 (m, 1H), 3.58 (s, 3H), 3.41 (s, 2H), 2.78 - 2.72 (m, 1H), 2.59 - 2.53 (m, 3H), 2.44 - 2.40 (m, 1H), 2.24 - 2.18 (m, 1H), 2.13 - 2.04 (m, 4H), 1.79 - 1.73 (m, 1H), 1.72 - 1.67 (m, 1H), 1.64 - 1.59 (m, 1H), 1.50 - 1.42 (m, 1H), 1.40 - 1.33 (m, 1H); MS (ESI): m/z 726.7 (M+H)+.
実施例36
化合物36aと化合物INT-8から、化合物33の合成を参照し、化合物36を得た。1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.55 - 7.50 (m, 2H), 7.49 - 7.43 (m, 6H), 7.39 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.68 (s, 1H), 5.73 (s, 2H), 3.83 - 3.74 (m, 2H), 3.66 - 3.63 (m, 1H), 3.58 (s, 3H), 3.42 (s, 2H), 2.77 - 2.73 (m, 1H), 2.56 (m, 3H), 2.45 - 2.39 (m, 1H), 2.23 - 2.16 (m, 1H), 2.15 - 2.04 (m, 4H), 1.79 - 1.73 (m, 1H), 1.72 - 1.66 (m, 1H), 1.64 - 1.59 (m, 1H), 1.50 - 1.42 (m, 1H), 1.41 - 1.33 (m, 1H); MS (ESI): m/z 726.7 (M+H)+.
実施例37
実施例38
実施例39
実施例40
実施例41
実施例42
実施例43
実施例44
化合物44aから、化合物INT-1j合成中の還元的アミノ化ステップを参照し、化合物44bを得た。MS (ESI): m/z 876.8 (M+H)+.
化合物44bから、化合物33合成中の最後2つのステップを参照し、化合物44を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.88 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.54 - 7.50 (m, 2H), 7.49 - 7.44 (m, 7H), 7.40 (d, J = 7.5 Hz, 2H), 7.17 (d, J = 7.0 Hz, 1H), 6.68 (s, 1H), 5.74 (s, 2H), 3.81 - 3.73 (m, 2H), 3.66 - 3.62 (m, 1H), 3.59 - 3.53 (m, 2H), 3.57 (s, 3H), 3.45 (s, 2H), 2.56 - 2.53 (m, 2H), 2.14 - 2.07 (m, 6H), 1.72 - 1.66 (m, 1H); MS (ESI): m/z 762.7 (M+H)+.
実施例45
実施例46
実施例47
実施例48
化合物48aと1,3-ジブロモ-2-クロロベンゼンから、化合物INT-3aの合成を参照し、化合物48bを得た。1H NMR (500 MHz, DMSO-d6) δ 10.27 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.85 - 7.81 (m, 1H), 7.48 - 7.34 (m, 4H), 2.66 (s, 3H).
化合物48b、化合物INT-2、化合物INT-8cと化合物INT-11から、化合物INT-3、化合物INT-8と化合物33の合成を参照し、化合物48を得た。1H NMR (500 MHz, DMSO-d6) δ 7.88 (s, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.67 (s, 1H), 7.53 - 7.38 (m, 5H), 7.35 (s, 1H), 7.30 - 7.23 (m, 2H), 7.14 (d, J = 7.0 Hz, 1H), 6.66 (s, 1H), 5.71 (s, 2H), 3.74 - 3.67 (m, 2H), 3.65 - 3.61 (m, 1H), 3.56 (s, 3H), 3.52 - 3.48 (m, 2H), 2.92 - 2.85 (m, 1H), 2.64 - 2.61 (m, 2H), 2.59 - 2.56 (m, 2H), 2.34 (s, 3H), 2.11 - 2.05 (m, 3H), 1.94 - 1.89 (m, 2H), 1.71 - 1.66 (m, 1H); MS (ESI): m/z 726.2 (M+H)+.
実施例49
実施例50
実施例51
実施例52
実施例53
実施例54
実施例55
実施例56
実施例57
実施例58
実施例59
実施例60
実施例61
実施例62
実施例63
実施例64
化合物64aと化合物INT-11から、化合物33の合成を参照し、化合物64を得た。1H NMR (500 MHz, DMSO-d6) δ 7.88 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.52 - 7.47 (m, 2H), 7.47 - 7.42 (m, 4H), 7.39 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 6.65 (s, 1H), 5.71 (s, 2H), 4.22 - 4.15 (m, 1H), 3.64 - 3.57 (m, 2H), 3.56 (s, 3H), 3.52 - 3.45 (m, 2H), 2.90 - 2.82 (m, 1H), 2.70 - 2.56 (m, 4H), 2.45 - 2.38 (m, 3H), 2.35 - 2.30 (m, 1H), 2.02 - 1.95 (m, 1H), 1.94 - 1.86 (m, 2H), 1.62 - 1.50 (m, 1H); MS (ESI): m/z 685.5 (M+H)+.
実施例65
実施例66
化合物66a、化合物INT-8cと化合物INT-11から、化合物INT-8と化合物33の合成を参照し、化合物66を得た。1H NMR (500 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.82 - 7.77 (m, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.53 - 7.48 (m, 2H), 7.47 - 7.40 (m, 6H), 7.35 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 6.65 (s, 1H), 5.71 (s, 2H), 3.73 (s, 2H), 3.56 (s, 3H), 3.52 - 3.47 (m, 2H), 3.16 - 3.12 (m, 2H), 2.93 - 2.84 (m, 1H), 2.67 - 2.61 (m, 2H), 2.57 (t, J = 6.5 Hz, 2H), 2.45 - 2.42 (m, 2H), 1.96 - 1.87 (m, 2H), 1.77 (s, 3H); MS (ESI): m/z 700.2 (M+H)+.
実施例67
化合物67a、化合物INT-8cと化合物INT-11から、化合物INT-8と化合物33の合成を参照し、化合物67を得た。1H NMR (500 MHz, DMSO-d6) δ 7.88 (s, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.53 - 7.48 (m, 2H), 7.47 - 7.39 (m, 6H), 7.35 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 6.65 (s, 1H), 5.71 (s, 2H), 3.77 - 3.71 (m, 2H), 3.64 - 3.59 (m, 1H), 3.56 (s, 3H), 3.52 - 3.48 (m, 2H), 2.91 - 2.83 (m, 1H), 2.66 - 2.60 (m, 2H), 2.55 - 2.51 (m, 2H), 2.47 - 2.45 (m, 2H), 2.15 - 2.04 (m, 3H), 1.95 - 1.88 (m, 2H), 1.72 - 1.64 (m, 1H); MS (ESI): m/z 712.6 (M+H)+.
実施例68
化合物68bから、化合物64の合成を参照し、化合物68を得た。1H NMR (500 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.53 - 7.48 (m, 2H), 7.47 - 7.43 (m, 4H), 7.43 - 7.40 (m, 2H), 7.35 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 6.94 (s, 1H), 6.65 (s, 1H), 5.71 (s, 2H), 3.74 (s, 2H), 3.56 (s, 3H), 3.54 - 3.52 (m, 2H), 3.05 (t, J = 6.5 Hz, 2H), 2.92 - 2.89 (m, 1H), 2.88 (s, 3H), 2.67 - 2.60 (m, 4H), 2.47 - 2.45 (m, 2H), 1.95 - 1.87 (m, 2H); MS (ESI): m/z 736.9 (M+H)+.
実施例69
化合物69aと(R)-3-ヒドロキシピロリジン塩酸塩から、化合物33の合成を参照し、化合物69を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.55 - 7.50 (m, 2H), 7.50 - 7.45 (m, 4H), 7.40 (d, J = 8.0 Hz, 2H), 7.37 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.67 (s, 1H), 5.73 (s, 2H), 4.20 - 4.15 (m, 1H), 3.66 - 3.59 (m, 2H), 3.58 (s, 3H), 3.53 (d, J = 14.5 Hz, 1H), 3.48 (d, J = 14.5 Hz, 1H), 2.96 - 2.91 (m, 1H), 2.74 (t, J = 8.5 Hz, 1H), 2.66 - 2.62 (m, 2H), 2.61 - 2.58 (m, 1H), 2.42 - 2.32 (m, 4H), 2.01 - 1.94 (m, 3H), 1.56 - 1.49 (m, 1H); MS (ESI): m/z 685.3 (M+H)+.
実施例70
化合物70aと化合物INT-2から、化合物33の合成を参照し、化合物70を得た。1H NMR (500 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.63 (s, 1H), 7.53 - 7.44 (m, 4H), 7.41 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 7.0 Hz, 1H), 7.09 - 7.07 (m, 1H), 7.06 - 7.02 (m, 1H), 6.67 (s, 1H), 5.71 (s, 2H), 3.80 (s, 3H), 3.62 - 3.59 (m, 4H), 3.58 - 3.56 (m, 4H), 2.95 - 2.89 (m, 1H), 2.77 - 2.71 (m, 1H), 2.70 - 2.65 (m, 1H), 2.58 - 2.52 (m, 2H), 2.47 - 2.43 (m, 2H), 2.11 - 2.02 (m, 3H), 1.98 - 1.92 (m, 2H), 1.67 - 1.60 (m, 1H); MS (ESI): m/z 742.7 (M+H)+.
実施例71
実施例72
-65oC条件下で、化合物72a (150 mg、0.40 mmol) の溶けたジクロロメタン (10 mL) 溶液にゆっくりと水素化ジイソブチルアルミニウム (1.5 Mのトルエン溶液、0.79 mL)を滴下した。得られた反応液は同じ温度下で半時間攪拌した。反応液はその後メタノール (2 mL) でクエンチし、室温に温度を上げた。酒石酸カリウムナトリウム (10% w/w水溶液、10 mL) 加入した後、激しく2時間攪拌した。得られた混合液中にさらにジクロロメタン (20 mL) を加入した。有機相はさらに飽和食塩水 (30 mL) で洗浄し、無水硫酸ナトリウムで乾燥した。濾液を濃縮した後無色油状物72bを得た (130 mg、収率: 93.6%)。MS (ESI): m/z 351.1 (M+H)+.
化合物72b (130 mg、0.37 mmol) の溶けたジクロロメタン (6 mL) 溶液にデス・マーチン酸化剤(157 mg、0.37 mmol) を加入した。反応液は25oC条件下で一時間攪拌した。反応液に飽和炭酸水素ナトリウム溶液 (20 mL)とジクロロメタン (20 mL) を加入した。得られた有機相はさらに飽和食塩水 (30 mL) で洗浄し、無水硫酸ナトリウムで乾燥した。濾液を濃縮し、残留物はシリカゲルカラムクロマトグラフィー (石油エーテル/酢酸エチル、v/v = 100/0 - 100/30) で分離して無色油状物72c (120 mg、収率: 92.8%)を得た。MS (ESI): m/z 349.1 (M+H)+.
化合物72c、O-tert-ブチル-L-セリン-t-ブチルと化合物INT-3から、化合物INT-1と化合物1の合成を参照し、化合物72を得た。1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.69 (s, 1H), 7.56 (d, J = 1.5 Hz, 1H), 7.52 - 7.44 (m, 8H), 7.29 - 7.25 (m, 1H), 7.18 (d, J = 7.0 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 5.77 (s, 2H), 3.90 (d, J = 14.0 Hz, 1H), 3.81 - 3.76 (m, 3H), 3.65 - 3.63 (m, 1H), 3.62 - 3.56 (m, 2H), 3.09 (t, J = 5.5 Hz, 1H), 2.57 - 2.54 (m, 2H), 2.13 - 2.07 (m, 3H), 1.74 - 1.67 (m, 1H); MS (ESI): m/z 672.5 (M+H)+.
実施例73
実施例74
化合物74aから、化合物73の合成を参照し、化合物74を得た。1H NMR (500 MHz, DMSO-d6) δ 8.49 (d, J = 2.0 Hz, 1H), 8.18 (s, 1H), 7.87 (s, 1H), 7.77 - 7.69 (m, 2H), 7.67 (s, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.48 - 7.44 (m, 6H), 7.15 (d, J = 7.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 5.77 (s, 2H), 3.91 (d, J = 13.5 Hz, 1H), 3.82 - 3.73 (m, 3H), 3.66 - 3.60 (m, 1H), 3.60 - 3.53 (m, 2H), 3.09 (t, J = 5.5 Hz, 1H), 2.55 (d, J = 6.0 Hz, 2H), 2.16 - 2.03 (m, 3H), 1.78 - 1.61 (m, 1H); MS (ESI): m/z 639.5 (M+H)+.
実施例75
実施例76
化合物76aから、化合物73の合成を参照し、化合物76を得た。1H NMR (500 MHz, DMSO-d6) δ 8.29 (s, 1H), 7.96 (s, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.67 (s, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.51-7.49 (m, 3H), 7.47 - 7.43 (m, 4H), 7.19 (d, J = 7.0 Hz, 1H), 6.13 (s, 1H), 6.11 (s, 1H), 3.87 (d, J = 15.4 Hz, 1H), 3.81 - 3.72 (m, 3H), 3.67 - 3.57 (m, 3H), 3.51 (s, 3H), 3.15 - 3.12 (m, 1H), 2.56 - 2.52 (m, 2H), 2.14 - 2.08 (m, 3H), 1.72 - 1.66 (m, 1H); MS (ESI): m/z 713.8 (M+H)+.
実施例77
化合物77aから、化合物73の合成を参照し、化合物77を得た。1H NMR (500 MHz, DMSO-d6) δ 7.86 (d, J = 8.5 Hz, 1H), 7.80 (s, 1H), 7.67 (s, 1H), 7.65 (s, 1H), 7.56 - 7.50 (m, 2H), 7.48 - 7.43 (m, 6H), 7.17 (d, J = 7.0 Hz, 1H), 5.81 (s, 2H), 3.95 (d, J = 14.5 Hz, 1H), 3.82-3.79 (m, 3H), 3.77 (s, 3H), 3.66 - 3.59 (m, 3H), 3.20 (t, J = 5.1 Hz, 1H), 2.57 - 2.58 (m, 2H), 2.13 - 2.07 (m, 3H), 1.74-1.66 (m, 1H); MS (ESI): m/z 736.7 (M+H)+.
実施例78
化合物78bから、化合物73の合成を参照し、化合物78を得た。1H NMR (500 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.74 (s, 1H), 7.66 (s, 1H), 7.52 - 7.48 (m, 2H), 7.46 - 7.43 (m, 5H), 7.14 - 7.11 (m, 3H), 5.67 (s, 2H), 3.94 (d, J = 14.2 Hz, 1H), 3.81 - 3.78 (m, 2H), 3.77 (s, 3H), 3.65 - 3.61 (m, 4H), 3.15 - 3.09 (m, 1H), 2.57 - 2.55 (d, J = 6.0 Hz, 2H), 2.13 - 2.07 (m, 3H), 1.73 - 1.66 (m, 1H); MS (ESI): m/z 702.7 (M+H)+.
実施例79
化合物79aから、化合物73の合成を参照し、化合物79を得た。1H NMR (500 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.93 (d, J = 1.6 Hz, 1H), 7.90 - 7.85 (m, 2H), 7.83 (s, 1H), 7.67 (s, 1H), 7.58 - 7.54 (m, 1H), 7.51 (d, J = 7.4 Hz, 1H), 7.48 - 7.42 (m, 5H), 7.18 (d, J = 7.1 Hz, 1H), 5.82 (s, 2H), 3.95 (d, J = 14.8 Hz, 1H), 3.81 - 3.74 (m, 3H), 3.65-3.62 (m, 1H), 3.61 - 3.56 (m, 2H), 3.12 (t, J = 5.3 Hz, 1H), 2.56 (d, J = 6.1 Hz, 2H), 2.13 - 2.07 (m, 3H), 1.72 - 1.66 (m, 1H); MS (ESI): m/z 697.5 (M+H)+.
実施例80
化合物80a (363 mg、2.00 mmol) の溶けたアセトニトリル (10 mL) 溶液にN-クロロスクシンイミド (321 mg、2.40 mmol)を加入した。反応液は70oC条件下で10時間攪拌した。反応液を濃縮し、残留物はシリカゲルカラムクロマトグラフィー (石油エーテル/酢酸エチル、v/v = 100/0 - 100/20) で分離して無色油状物80b を得た(420 mg、収率: 97.2%)。1H NMR (500 MHz, DMSO-d6) δ 8.09 (s, 1H), 3.91 (s, 3H), 3.80 (s, 3H), 2.51 (s, 3H).
化合物80bから、化合物73の合成を参照し、化合物80を得た。1H NMR (500 MHz, DMSO-d6) δ 7.86 (s, 1H), 7.84 (s, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.67 (s, 1H), 7.53 - 7.51 (m, 1H), 7.48 - 7.44 (m, 7H), 7.14 (d, J = 7.0 Hz, 1H), 5.82 (s, 2H), 3.79 - 3.76 (m, 2H), 3.66 - 3.55 (m, 5H), 3.38 (s, 3H), 3.13 - 3.08 (m, 1H), 2.58 - 2.54 (m, 2H), 2.13 - 2.08 (m, 3H), 1.73 - 1.67 (m, 1H); MS (ESI): m/z 703.2 (M+H)+.
実施例81
化合物81a (300 mg、1.50 mmol) の溶けたジクロロメタン (8 mL) 溶液に塩化オキサリル (345 mg、2.72 mmol)とN, N-ジメチルホルムアミド1滴を加入した。反応液は25oC条件下で3時間攪拌した。その後反応液を濃縮した。得られた残留物はジクロロメタン (3 mL) で再溶解後、4-ブロモインダゾール (265 mg、1.35 mmol),4-ジメチルアミノピリジン (18.3 mg、0.15 mmol)とトリエチルアミン (302 mg、2.99 mmol) を溶解したジクロロメタン (8 mL) 溶液に加入した。反応液は25oC条件下で16時間攪拌した。反応液を濃縮し、残留物はシリカゲルカラムクロマトグラフィー (石油エーテル/酢酸エチル、v/v = 100/0 - 100/20) で分離して白色の固体81b (410 mg、収率: 72.2%)を得た。
化合物81c (120 mg、0.26 mmol)とO-tert-ブチル-L-セリン-t-ブチル (171 mg、0.78 mmol) の溶けたN’N-ジメチルホルムアミド (2 mL) に炭酸カリウム (72 mg、0.52 mmol)を加入した。反応液は25oC条件下で一時間攪拌した。反応液に酢酸エチル (20 mL)と水 (20 mL)を加入した。有機相はさらに飽和食塩水 (20 mL) で洗浄し、無水硫酸ナトリウムで乾燥した。残留物はシリカゲル薄層クロマトグラフィー板 (石油エーテル/酢酸エチル、v/v = 4/1) で分離して白色の固体81d (70 mg、収率: 45.0%)を得た。MS (ESI): m/z 594.4 (M+H)+.
化合物81dから、INT-1合成過程におけるホウ素エステル化ステップを参照し、化合物81eを得た。MS (ESI): m/z 642.8 (M+H)+.
90oC条件と窒素雰囲気下で、化合物81e (35 mg、0.038 mmol)、化合物INT-3 (18.9 mg、0.038 mmol)、Pd(dppf)Cl2 (2.8 mg、0.0038 mmol)とフッ化カリウム(6.7 mg、0.11 mmol) を混合した1.4-ジオキサン (4 mL) 溶液を16時間攪拌した。反応液を濃縮し、残留物はシリカゲル薄層クロマトグラフィー板 (ジクロロメタン/メタノール、v/v = 20/1) で分離して無色油状物81f (20 mg、収率: 36.7%)を得た。MS (ESI): m/z 928.2 (M+H)+.
化合物81fから、化合物1合成の最後のステップ脱Boc保護基ステップを参照し、化合物81を得た。1H NMR (500 MHz, DMSO-d6) δ 8.49 (d, J = 8.0 Hz, 1H), 8.27 (s, 1H), 7.82 (t, J = 8.0 Hz, 1H), 7.65 (s, 1H), 7.57 (s, 1H), 7.55 - 7.53 (m, 1H), 7.52 - 7.49 (m, 3H), 7.47 - 7.40 (m, 5H), 3.79 (s, 3H), 3.76 - 3.74 (m, 2H), 3.62 - 3.59 (m, 3H), 3.50 - 3.48 (m, 2H), 3.12 - 3.11 (m, 1H), 2.53 - 2.52 (m, 2H), 2.10 - 2.06 (m, 3H), 1.69 - 1.65 (m, 1H); MS (ESI): m/z 716.0 (M+H)+.
実施例82
化合物82aと化合物INT-3から、化合物81合成過程における最後2つのステップを参照し、化合物82を得た。1H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J = 7.0 Hz, 1H), 8.23 (s, 1H), 7.88 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.55 - 7.45 (m, 7H), 7.15 (d, J = 7.0 Hz, 1H), 5.93 (s, 2H), 4.28 - 4.26 (m, 1H), 3.85 - 3.75 (m, 3H), 3.67 - 3.60 (m, 2H), 3.39 (s, 3H), 2.59 (d, J = 6.2 Hz, 2H), 2.14 - 2.07 (m, 3H), 1.72-1.69 (m, 1H); MS (ESI): m/z 717.2 (M+H)+.
実施例83
化合物83a、O-tert-ブチル-L-セリン-t-ブチルと化合物INT-3から、化合物INT-8と化合物1の合成を参照し、化合物83を得た。1H NMR (500 MHz, DMSO-d6) δ 7.84 - 7.79 (m, 1H), 7.66 (s, 1H), 7.62 - 7.58 (m, 1H), 7.52 - 7.43 (m, 8H), 7.17 (d, J = 7.0 Hz, 1H), 6.84 (s, 1H), 5.62 (s, 2H), 3.91 - 3.79 (m, 4H), 3.67 (s, 3H), 3.65 - 3.56 (m, 3H), 3.17 - 3.15 (m, 1H), 2.60 - 2.55 (m, 2H), 2.14 - 2.09 (m, 3H), 1.73 - 1.67 (m, 1H); MS (ESI): m/z 720.6 (M+H)+.
実施例84
化合物84aから、化合物83の合成を参照し、化合物84を得た。1H NMR (500 MHz, DMSO-d6) δ 7.85 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.59 - 7.55 (m, 1H), 7.50 - 7.47 (m, 2H), 7.45 - 7.39 (m, 6H), 7.11 (d, J = 7.0 Hz, 1H), 6.84 (d, J = 1.5 Hz, 1H), 5.75 - 5.68 (m, 1H), 5.70 (s, 1H), 3.89 - 3.86 (m, 1H), 3.79 - 3.75 (m, 3H), 3.65 (s, 3H), 3.62 - 3.59 (m, 3H), 3.14 - 3.12 (m, 1H), 2.54 (d, J = 6.0 Hz, 2H), 2.11 - 2.06 (m, 3H), 1.70 - 1.65 (m, 1H); MS (ESI): m/z 736.5 (M+H)+.
実施例85
実施例86
化合物86a、化合物INT-3とエタノールアミンから、化合物INT-7と化合物22の合成を参照し、化合物86を得た。1H NMR (500 MHz, DMSO-d6) δ 7.88 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.67 (s, 1H), 7.53 - 7.41 (m, 9H), 7.15 (d, J = 6.9 Hz, 1H), 6.94 (s, 1H), 5.70 (s, 2H), 4.26 (s, 2H), 4.01 (s, 2H), 3.81 - 3.72 (m, 2H), 3.67 - 3.58 (m, 3H), 2.86 (t, J = 5.4 Hz, 2H), 2.57 - 2.50 (m, 2H), 2.13 - 2.04 (m, 3H), 1.72 - 1.64 (m, 1H); MS (ESI): m/z 702.4 (M+H)+.
実施例87
化合物87aと化合物INT-11から、化合物33の合成を参照し、化合物87を得た。1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.55 - 7.47 (m, 4H), 7.39 (d, J = 7.5 Hz, 1H), 7.36 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 7.08 (s, 1H), 7.06 (d, J = 7.5 Hz, 1H), 6.68 (s, 1H), 5.73 (s, 2H), 4.23 - 4.17 (m, 1H), 3.82 (s, 3H), 3.64 - 3.56 (m, 5H), 3.55 - 3.47 (m, 2H), 2.88 - 2.82 (m, 1H), 2.75 - 2.69 (m, 1H), 2.67 - 2.61 (m, 3H), 2.47 - 2.43 (m, 2H), 2.41 - 2.36 (m, 2H), 2.05 - 1.97 (m, 1H), 1.95 - 1.89 (m, 2H), 1.58 - 1.52 (m, 1H); MS (ESI): m/z 715.7 (M+H)+.
実施例88
化合物88aと化合物INT-11から、化合物33の合成を参照し、化合物88を得た。1H NMR (500 MHz, DMSO-d6) δ 7.92 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.55 - 7.47 (m, 4H), 7.41 (d, J = 7.5 Hz, 1H), 7.37 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 7.11 (s, 1H), 7.09 - 7.04 (m, 1H), 6.69 (s, 1H), 5.73 (s, 2H), 3.84 (s, 3H), 3.79 (d, J = 3.5 Hz, 2H), 3.58 (s, 3H), 3.56 - 3.47 (m, 4H), 2.94 - 2.85 (m, 1H), 2.70 - 2.62 (m, 4H), 2.50 - 2.48 (m, 2H), 1.96 - 1.90 (m, 2H); MS (ESI): m/z 689.6 (M+H)+.
実施例89
化合物89a (150 mg、0.16 mmol) の溶けた酢酸 (3 mL) 溶液に亜鉛粉 (32 mg、0.49 mmol) を加入した。反応液は70oC条件下で半時間攪拌した。反応液を濃縮し、残留物は分取薄層クロマトグラフィー (ジクロロメタン/メタノール、v/v = 20/1)で分離して黄色油状物89bを得た (30 mg、収率: 20.7%)。MS (ESI): m/z 895.9 (M+H)+.
化合物89bから、化合物1合成過程中最後のステップ脱Boc保護基ステップを参照し、化合物89を得た。1H NMR (500 MHz, DMSO-d6) δ 7.88 (s, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.67 (s, 1H), 7.54 - 7.42 (m, 8H), 7.14 (d, J = 6.9 Hz, 1H), 6.80 (s, 1H), 6.68 (s, 1H), 5.55 (s, 2H), 5.00 - 4.95 (m, 1H), 3.84 - 3.73 (m, 4H), 3.63 (s, 3H), 3.60 - 3.51 (m, 3H), 3.04 - 3.02 (m, 1H), 2.56 - 2.52 (m, 2H), 2.13 - 2.06 (m, 3H), 1.73-1.66 (m, 1H); MS (ESI): m/z 683.1 (M+H)+.
実施例90
化合物90aと化合物INT-11から、化合物33の合成を参照し、化合物90を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.66 (s, 1H), 7.49 (t, J = 8.5 Hz, 1H), 7.43 - 7.36 (m, 3H), 7.34 - 7.30 (m, 2H), 7.10 (d, J = 7.0 Hz, 1H), 7.03 (s, 1H), 7.00 (d, J = 7.0 Hz, 1H), 6.67 (s, 1H), 5.73 (s, 2H), 3.84 (s, 3H), 3.82 - 3.77 (m, 2H), 3.70 - 3.65 (m, 1H), 3.58 (s, 3H), 3.53 (d, J = 9.0 Hz, 2H), 2.95 - 2.88 (m, 1H), 2.68 - 2.62 (m, 4H), 2.53 - 2.52 (m, 2H), 2.16 - 2.08 (m, 3H), 2.00 (s, 3H), 1.97 - 1.91 (m, 2H), 1.75 - 1.68 (m, 1H); MS (ESI): m/z 722.3 (M+H)+.
実施例91
実施例92
化合物92aとトランス-4-アミノシクロヘキサンカルボン酸メチル塩酸塩から、化合物44の合成を参照し、化合物92を得た。1H NMR (500 MHz, DMSO-d6) δ 8.18 (s, 1H), 7.96 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.54 - 7.48 (m, 4H), 7.41 (d, J = 7.5 Hz, 1H), 7.17 (d, J = 7.0 Hz, 1H), 7.09 (d, J = 1.5 Hz, 1H), 7.08 - 7.04 (m, 1H), 6.11 - 6.08 (m, 3H), 3.82 (s, 3H), 3.78 - 3.72 (m, 2H), 3.66 - 3.62 (m, 1H), 3.51 - 3.49 (m, 2H), 3.48 (s, 3H), 2.57 (d, J = 6.0 Hz, 2H), 2.46 - 2.36 (m, 2H), 2.13 (s, 3H), 2.11 - 2.07 (m, 3H), 1.94 - 1.89 (m, 2H), 1.82 - 1.77 (m, 2H), 1.72 - 1.65 (m, 1H), 1.32 - 1.26 (m, 4H); MS (ESI): m/z 795.7 (M+H)+.
実施例93
実施例94
実施例95
実施例96
実施例97
化合物97aから、化合物INT-8aのアルキル基化反応ステップを参照し、化合物97bを得た。1H NMR (500 MHz, DMSO-d6) δ 10.40 (s, 1H), 7.86 - 7.82 (m, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.47 - 7.43 (m, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.24 (d, J = 1.4 Hz, 1H), 7.10 - 7.06 (m, 1H), 4.23 (q, J = 7.0 Hz, 2H), 1.38 (t, J = 7.0 Hz, 3H).
化合物97b、化合物INT-2、化合物INT-8cと止血環酸メチル塩酸塩から、化合物48の合成を参照し、化合物97を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.55 - 7.44 (m, 4H), 7.39 (d, J = 7.7 Hz, 1H), 7.36 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 7.05 (d, J = 1.7 Hz, 1H), 7.04 - 7.00 (m, 1H), 6.67 (s, 1H), 5.71 (s, 2H), 4.08 (q, J = 6.9 Hz, 2H), 3.74 - 3.68 (m, 2H), 3.64 - 3.59 (m, 1H), 3.56 (s, 3H), 3.34 (s, 2H), 2.55 - 2.53 (m, 2H), 2.13 - 2.03 (m, 9H), 1.86 - 1.75 (m, 4H), 1.72 - 1.66 (m, 1H), 1.46 - 1.40 (m, 1H), 1.33 (t, J = 6.9 Hz, 3H), 1.27 - 1.21 (m, 2H), 0.84 - 0.75 (m, 2H); MS (ESI): m/z 812.8 (M+H).
実施例98
実施例99
化合物99aと化合物INT-9から、化合物44の合成を参照し、化合物99を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.66 (s, 1H), 7.54 - 7.45 (m, 4H), 7.40 (d, J = 7.5 Hz, 1H), 7.33 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 7.08 - 7.06 (m, 1H), 7.05 - 7.02 (m, 1H), 6.67 (s, 1H), 5.71 (s, 2H), 3.81 (s, 3H), 3.75 - 3.68 (m, 2H), 3.64 - 3.60 (m, 1H), 3.56 (s, 3H), 3.48 (s, 2H), 2.68 - 2.62 (m, 1H), 2.55 - 2.51 (m, 2H), 2.47 - 2.42 (m, 2H), 2.40 - 2.34 (m, 1H), 2.28 - 2.23 (m, 2H), 2.15 - 2.05 (m, 4H), 1.97 - 1.89 (m, 1H), 1.72 - 1.64 (m, 1H), 1.37 - 1.29 (m, 1H); MS (ESI): m/z 756.7 (M+H).
実施例100
化合物100a (40 mg、0.050 mmol) の溶けたN,N-ジメチルホルムアミド (2 mL) にたホルムアルデヒド (34%水溶液、0.10 mL)、酢酸 (6.0 mg、0.10 mmol)と三酢酸水素化ホウ素ナトリウム (42 mg、0.20 mmol) を加入した。反応液は25oC条件下で2時間攪拌した。反応液に飽和炭酸水素ナトリウム溶液 (20 mL) 加入し、酢酸エチルで抽出した (20 mL x 2)。合併有機相は飽和食塩水 (30 mL) で洗浄し、無水硫酸ナトリウムで乾燥し、濃縮し、棕色油状物100b (35 mg、収率: 84.5%)を得た。MS (ESI): m/z 826.7 (M+H).
化合物100bから、化合物33合成過程におけるエステル加水分解ステップを参照し、化合物100を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.55 - 7.45 (m, 5H), 7.44 (d, J = 7.5 Hz, 1H), 7.36 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 7.09 - 7.07 (m, 1H), 7.06 - 7.03 (m, 1H), 6.67 (s, 1H), 5.71 (s, 2H), 3.80 (s, 3H), 3.74 - 3.68 (m, 1H), 3.56 (s, 3H), 3.53 - 3.49 (m, 2H), 3.36 (s, 2H), 2.44 - 2.39 (m, 1H), 2.36 - 2.30 (m, 1H), 2.17 (s, 3H), 2.11 - 2.05 (m, 9H), 1.87 - 1.78 (m, 4H), 1.70 - 1.64 (m, 1H), 1.48 - 1.40 (m, 1H), 1.32 - 1.21 (m, 2H), 0.86 - 0.76 (m, 2H); MS (ESI): m/z 812.7 (M+H).
実施例101
実施例102
化合物102a、化合物INT-8cと止血環酸メチル塩酸塩から、化合物INT-8と化合物44の合成を参照し、化合物102を得た。1H NMR (500 MHz, DMSO-d6) δ 7.93 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.63 (s, 1H), 7.56 - 7.48 (m, 4H), 7.38 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.77 (s, 2H), 6.70 (s, 1H), 5.73 (s, 2H), 3.82 (s, 6H), 3.76 - 3.70 (m, 2H), 3.60 - 3.56 (m, 4H), 3.36 (s, 2H), 2.53 - 2.52 (m, 2H), 2.13 - 2.04 (m, 9H), 1.89 - 1.79 (m, 4H), 1.70 - 1.61 (m, 1H), 1.50 - 1.42 (m, 1H), 1.32 - 1.23 (m, 2H), 0.87 - 0.77 (m, 2H); MS (ESI): m/z 828.5 (M+H).
実施例103
化合物103aから、化合物92の合成を参照し、化合物103を得た。1H NMR (500 MHz, DMSO-d6) δ 7.98 (s, 1H), 7.96 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.66 (s, 1H), 7.56 - 7.47 (m, 4H), 7.40 (d, J = 7.6 Hz, 1H), 7.18 (d, J = 7.0 Hz, 1H), 7.07 (d, J = 1.6 Hz, 1H), 7.06 - 7.02 (m, 1H), 6.31 (s, 1H), 6.14 (s, 2H), 3.82 (s, 3H), 3.76 - 3.67 (m, 2H), 3.64 - 3.59 (m, 1H), 3.48 (s, 2H), 3.47 (s, 3H), 3.21 (s, 3H), 2.56 - 2.52 (m, 2H), 2.39 - 2.33 (m, 1H), 2.11 (s, 3H), 2.11 - 2.07 (m, 3H), 2.07 - 2.04 (m, 1H), 1.94 - 1.87 (m, 2H), 1.82 - 1.76 (m, 2H), 1.71 - 1.64 (m, 1H), 1.32 - 1.23 (m, 4H); MS (ESI): m/z 828.2 (M+H).
実施例104
実施例105
実施例106
実施例107
実施例108
実施例109
化合物109aと化合物INT-9から、化合物44の合成を参照し、化合物109を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.54 - 7.46 (m, 4H), 7.40 (d, J = 7.5 Hz, 1H), 7.37 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 7.08 - 7.06 (m, 1H), 7.05 - 7.02 (m, 1H), 6.67 (s, 1H), 5.71 (s, 2H), 3.81 (s, 3H), 3.71 (d, J = 3.0 Hz, 2H), 3.64 - 3.59 (m, 1H), 3.57 (s, 3H), 3.43 (s, 2H), 2.56 - 2.52 (m, 2H), 2.36 - 2.31 (m, 1H), 2.21 - 2.16 (m, 2H), 2.13 - 2.04 (m, 3H), 2.07 (s, 3H), 1.98 - 1.91 (m, 1H), 1.72 - 1.66 (m, 1H), 1.61 - 1.53 (m, 2H), 1.51 - 1.39 (m, 6H); MS (ESI): m/z 798.3 (M+H).
実施例110
化合物110aから、化合物INT-8aのアルキル基化反応ステップを参照し、化合物110bを得た。1H NMR (500 MHz, DMSO-d6) δ 10.21 (s, 1H), 8.13 (s, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.48 - 7.24 (m, 2H), 6.80 (s, 1H), 5.78 (s, 2H), 4.55 - 4.32 (m, 1H), 1.19 (d, J = 6.0 Hz, 6H).
化合物110b、化合物INT-6と止血環酸メチル塩酸塩から、化合物INT-8と化合物44の合成を参照し、化合物110を得た。1H NMR (500 MHz, DMSO-d6) δ 7.92 (s, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.64 (s, 1H), 7.54 - 7.45 (m, 4H), 7.43 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.15 (d, J = 7.0 Hz, 1H), 7.12 (s, 1H), 7.08 (d, J = 7.5 Hz, 1H), 6.41 (s, 1H), 5.72 (s, 2H), 4.20 - 4.12 (m, 1H), 3.86 - 3.82 (m, 2H), 3.84 (s, 3H), 3.71 - 3.66 (m, 1H), 3.33 (s, 2H), 2.73 - 2.63 (m, 2H), 2.14 - 2.06 (m, 9H), 1.87 - 1.77 (m, 4H), 1.72 - 1.68 (m, 1H), 1.48 - 1.39 (m, 1H), 1.30 - 1.22 (m, 2H), 1.05 (d, J = 6.0 Hz, 6H), 0.86 - 0.76 (m, 2H); MS (ESI): m/z 826.3 (M+H).
実施例111
化合物111a、化合物INT-2と止血環酸メチル塩酸塩から、化合物INT-8と化合物44の合成を参照し、化合物111を得た。1H NMR (500 MHz, DMSO-d6) δ 7.86 (s, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.67 (s, 1H), 7.53 - 7.49 (m, 2H), 7.48 - 7.42 (m, 6H), 7.18 - 7.12 (m, 2H), 6.88 (d, J = 6.0 Hz, 1H), 5.69 (s, 2H), 3.80 - 3.72 (m, 2H), 3.66 - 3.60 (m, 1H), 3.65 (s, 3H), 3.36 (s, 2H), 2.56 - 2.53 (m, 2H), 2.14 - 2.07 (m, 6H), 2.09 (s, 3H), 1.89 - 1.78 (m, 4H), 1.73 - 1.66 (m, 1H), 1.50 - 1.40 (m, 1H), 1.31 - 1.22 (m, 2H), 0.85 - 0.76 (m, 2H); MS (ESI): m/z 752.3 (M+H).
実施例112
化合物112a、化合物INT-6と止血環酸メチル塩酸塩から、化合物INT-8と化合物44の合成を参照し、化合物112を得た。1H NMR (500 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.66 (s, 1H), 7.55 - 7.46 (m, 4H), 7.44 (d, J = 7.5 Hz, 1H), 7.15 (d, J = 7.0 Hz, 1H), 7.12 (s, 2H), 7.09 (d, J = 7.5 Hz, 1H), 6.60 (s, 1H), 5.66 (s, 2H), 3.88 - 3.82 (m, 2H), 3.85 (s, 3H), 3.72 - 3.67 (m, 1H), 3.57 (s, 3H), 3.43 - 3.40 (m, 2H), 2.67 (d, J = 6.0 Hz, 2H), 2.25 (s, 3H), 2.18 - 2.04 (m, 9H), 1.89 - 1.80 (m, 4H), 1.76 - 1.68 (m, 1H), 1.55 - 1.45 (m, 1H), 1.32 - 1.23 (m, 2H), 0.86 - 0.75 (m, 2H); MS (ESI): m/z 778.4 (M+H).
実施例113
実施例114
実施例115
実施例116
実施例117
実施例118
化合物118bと化合物INT-9から、化合物44の合成を参照し、化合物118を得た。1H NMR (500 MHz, DMSO-d6) δ 7.90 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.53 - 7.45 (m, 4H), 7.40 (d, J = 7.5 Hz, 1H), 7.36 (s, 1H), 7.15 (d, J = 7.5 Hz, 1H), 7.08 - 7.06 (m, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.67 (s, 1H), 5.71 (s, 2H), 3.81 (s, 3H), 3.75 - 3.67 (m, 2H), 3.65 - 3.59 (m, 1H), 3.56 (s, 3H), 3.34 (s, 2H), 2.56 - 2.52 (m, 2H), 2.14 - 2.03 (m, 10H), 1.80 - 1.73 (m, 2H), 1.72 - 1.65 (m, 3H), 1.58 - 1.53 (m, 1H), 1.44 - 1.36 (m, 1H), 0.97 - 0.86 (m, 2H), 0.83 - 0.75 (m, 2H); MS (ESI): m/z 812.2 (M+H).
実施例119
化合物120bと化合物INT-9から、化合物44の合成を参照し、化合物120を得た。1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.66 (s, 1H), 7.56 - 7.47 (m, 4H), 7.42 (d, J = 7.7 Hz, 1H), 7.39 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 7.10 (s, 1H), 7.09 - 7.05 (m, 1H), 6.77 - 6.71 (m, 1H), 6.69 (s, 1H), 5.73 (s, 2H), 5.72 - 5.66 (m, 1H), 3.84 (s, 3H), 3.82 - 3.73 (m, 2H), 3.68 - 3.63 (m, 1H), 3.59 (s, 3H), 3.53 - 3.42 (m, 2H), 2.61 - 2.56 (m, 2H), 2.44 - 2.36 (m, 1H), 2.17 - 2.06 (m, 7H), 1.86 - 1.75 (m, 4H), 1.75 - 1.66 (m, 1H), 1.40 - 1.27 (m, 2H), 1.18 - 1.08 (m, 2H); MS (ESI): m/z 810.2 (M+H)。
化合物122:1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.67 (s, 1H), 7.55 - 7.45 (m, 4H), 7.41 (d, J = 7.5 Hz, 1H), 7.31 (s, 1H), 7.17 (d, J = 7.0 Hz, 1H), 7.09 - 7.07 (m, 1H), 7.07 - 7.03 (m, 1H), 6.66 (s, 1H), 5.71 (s, 2H), 3.83 (s, 3H), 3.73 - 3.72 (m, 2H), 3.68 (s, 2H), 3.65 - 3.60 (m, 1H), 3.59 (s, 3H), 2.56 - 2.53 (m, 2H), 2.46 - 2.42 (m, 1H), 2.14 - 2.03 (m, 5H), 1.93 - 1.87 (m, 2H), 1.83 - 1.78 (m, 2H), 1.72 - 1.67 (m, 1H), 1.38 - 1.30 (m, 2H), 1.26 - 1.20 (m, 2H), 0.40 - 0.35 (m, 2H), 0.26 - 0.17 (m, 2H); MS (ESI): m/z 810.2 (M+H)。
化合物135aと4-アミノビシクロ[2.2.2]オクタン-1-カルボン酸メチルエステル塩酸塩から、化合物101の合成を参照し、化合物135を得た。1H NMR (500 MHz, DMSO-d6) δ 7.85 (s, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.69 (s, 1H), 7.63 (s, 1H), 7.57 - 7.43 (m, 4H), 7.12 (d, J = 7.0 Hz, 1H), 6.96 (s, 1H), 6.94 (d, J = 8.5 Hz, 1H), 5.78 (s, 2H), 3.85 (s, 3H), 3.74 - 3.73 (m, 2H), 3.58 - 3.56 (m, 3H), 3.37 (s, 3H), 2.51-2.50 (m, 2H), 2.10 - 2.03 (m, 3H), 1.99 (s, 3H), 1.70 - 1.67 (m, 6H), 1.64 - 1.62 (m, 1H), 1.54 - 1.51 (m, 6H); MS (ESI): m/z 829.2 (M+H)。
化合物137aと4-アミノビシクロ[2.2.2]オクタン-1-カルボン酸メチルエステル塩酸塩から、化合物101の合成を参照し、化合物137を得た。1H NMR (500 MHz, DMSO-d6) δ 7.83 - 7.80 (m, 3H), 7.70 - 7.65 (m, 3H), 7.55 (t, J = 7.5 Hz, 1H), 7.50 - 7.47 (m, 2H), 7.31 (d, J = 7.4 Hz, 1H), 7.14 (d, J = 7.0 Hz, 1H), 5.80 (s, 2H), 3.92 (s, 3H), 3.73 - 3.71 (m, 2H), 3.65 - 3.63 (m, 1H), 3.39 (s, 3H), 3.36 (brs, 2H), 2.56 (d, J = 6.0 Hz, 2H), 2.14 - 2.07 (m, 3H), 2.00 (s, 3H), 1.72-1.68 (m, 7H), 1.56-1.52 (m, 6H); MS (ESI): m/z 812.1 (M+H)。
化合物156bから、化合物INT-10と化合物133の合成を参照し、化合物156を得た。1H NMR (500 MHz, DMSO-d6) δ 8.24 (d, J = 1.7 Hz, 1H), 7.94 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.61 - 7.48 (m, 5H), 7.40 (s, 1H), 7.18 (d, J = 7.0 Hz, 1H), 6.68 (s, 1H), 5.72 (s, 2H), 3.88 (s, 3H), 3.86 (s, 2H), 3.65 - 3.60 (m, 1H), 3.58 (s, 3H), 3.43 (s, 2H), 2.66 - 2.56 (m, 2H), 2.15 - 2.05 (m, 3H), 2.00 (s, 3H), 1.77 - 1.67 (m, 7H), 1.61 - 1.52 (m, 6H); MS (ESI): m/z 811.1 (M+H)。
化合物157aから、155cの合成を参照し、化合物157cを得た。1H NMR (500 MHz, DMSO-d6) δ 10.27 (s, 1H), 7.31 (d, J = 1.5 Hz, 1H), 6.19 (d, J = 1.5 Hz, 1H), 4.11 - 4.07 (m, 2H), 3.96 - 3.92 (m, 2H), 3.90 (s, 3H)。
化合物157eから、化合物133の合成を参照し、化合物157を得た。1H NMR (500 MHz, DMSO-d6) δ 7.87 (s, 1H), 7.81 (d, J = 7.5 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.68 - 7.63 (m, 2H), 7.56 - 7.49 (m, 3H), 7.30 (d, J = 7.5 Hz, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.58 (s, 1H), 5.76 (s, 2H), 3.90 (s, 3H), 3.70 (d, J = 3.5 Hz, 2H), 3.64 - 3.61 (m, 1H), 3.60 (s, 3H), 3.45 (s, 2H), 2.54 (d, J = 6.0 Hz, 2H), 2.14 - 2.05 (m, 3H), 1.89 (s, 3H), 1.74 - 1.69 (m, 6H), 1.69 - 1.64 (m, 1H), 1.62 - 1.57 (m, 6H); MS (ESI): m/z 829.3 (M+H)。
化合物165 bと3-ブロモ-2-メチルフェノールから、化合物INT-10と化合物133との合成を参照し、化合物165を得た。1H NMR (500 MHz, DMSO-d6) δ 8.44 (s, 1H), 7.83 (s, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.68 (s, 1H), 7.52 - 7.48 (m, 1H), 7.46 - 7.43 (m, 1H), 7.42 - 7.38 (m, 2H), 7.37 - 7.33 (m, 1H), 7.19 (s, 1H), 7.09 (d, J = 6.9 Hz, 1H), 6.66 (s, 1H), 5.72 (s, 2H), 3.92 (s, 3H), 3.78 - 3.69 (m, 2H), 3.67 - 3.60 (m, 1H), 3.58 (s, 3H), 3.43 - 3.38 (m, 2H), 2.55 (d, J = 6.0 Hz, 2H), 2.15 - 2.06 (m, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.77 - 1.71 (m, 6H), 1.71 - 1.65 (m, 1H), 1.61 - 1.54 (m, 6H); MS (ESI): m/z 791.0 (M+H)。
化合物173aとトランス-4-アミノシクロヘキサンカルボン酸メチル塩酸塩から、化合物72cの合成と化合物44的還元的アミノ化を参照し、化合物173cを得た。MS (ESI): m/z 549.0 (M+H)。
細胞レベルのPD-1/PD-L1シグナル阻害の生物学的活性検出
本検出方法は本発明に記載の化合物の細胞レベルの生物学的活性評価に用いる。
本検出方法はルシフェラーゼレポーター遺伝子アッセイを用いて、細胞レベルのPD-1/PD-L1シグナル阻害に対する化合物の生物学的活性を検出する。PD-1/NFAT-レポーター-Jurkat細胞がヒトPD-1を安定的に発現し、且つNFATエレメントによって調節されるルシフェラーゼレポーター遺伝子を発現する。TCRアクティベーター/PD-L1-CHO細胞がヒトPD-L1及びTCRアクティベーターを安定的に発現する。2つの細胞株を共培養すると、PD-1/PD-L1の結合がTCRシグナル伝達経路を阻害し、そして下流のNFATによってコントロールされるルシフェラーゼレポーター遺伝子発現を阻害する。PD-1/PD-L1抗体又は阻害薬を加えると、このような阻害が逆転され、ルシフェラーゼが発現されるため、ルシフェラーゼ活性に対するPD-1/PD-L1阻害薬の影響を検出できる。
PD-1/NFAT-レポーター-Jurkat細胞(カタログ番号60535)及びTCRアクティベーター/PD-L1-CHO細胞(カタログ番号60536)はBPSバイオサイエンス社から購入した。PD-L1抗体(アテゾリズマブ、カタログ番号A2004)はセレック(Selleck)社から購入した。ルシフェラーゼ検出試薬(ONE-Glo(登録商標)Luciferase Assay System、カタログ番号E6120)はプロメガ社から購入した。多目的マイクロプレートリーダー(モデルSpectraMax i3x)はモレキュラーデバイス社から購入した。
通常の細胞培養実験手順に従ってPD-1/NFAT-レポーター-Jurkat細胞及びTCRアクティベーター/PD-L1-CHO細胞を培養した。
Claims (29)
-
L2、L3は-(CRCRD)p、-(CRCRD)p-NRa-(CRCRD)q-、-(CRCRD)p-O-(CRCRD)q-、-C(O)-から選ばれ、
W1、W2はそれぞれ独立してCRL又はNを表し、
R1はそれぞれ独立して水素、ハロゲン、ニトロ基、シアノ基又は-NRaRb、又は0、1、2、又は3つの置換基によって置換されたC1-C6アルキル基、C3-C6シクロアルキル基、-O(C1-C6アルキル基)、-O(C0-C6アルキレン)(C5-C10アリール基)、-O(C0-C6アルキレン)(5-10員ヘテロアリール基)、-O(C0-C6アルキレン)(C3-C6シクロアルキル基)又は-O(C0-C6アルキレン)(3-6員ヘテロシクロアルキル基)を表し、前記置換基は-ORa、シアノ基、オキソ、ハロゲン、C1-C6アルキル基、-(C1-C6アルキレン)ORa、シアノ基C1-C6アルキル基、C1-C6ハロアルキル基、C3-C8シクロアルキル基、-C(O)Ra、-(C1-C6アルキレン)C(O)Ra、-C(O)ORa、-(C1-C6アルキル基)C(O)ORa、-NRaRb、-(C1-C6アルキレン)NRaRb、-C(O)NRaRb、-SO2Ra、-C(O)NRaSO2Rb、-NRaC(O)Rbから選ばれ、
R2、R3、R4、R5はそれぞれ独立して水素、ハロゲン、ニトロ基、シアノ基、-NRaRb、-SO2Ra、-S(O)Ra、-P(O)RaRb、C1-C6アルキル基、-O(C1-C6アルキル基)、-O(C3-C6シクロアルキル基)、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表し、
Cyは0、1、2、又は3つのR6によって置換されたベンゼン環又は六員ヘテロアリール基を表し、前記六員ヘテロアリール基は所望により1又は2つの窒素原子を含み、前記R6は水素、ハロゲン、ニトロ基、シアノ基、-NRaRb、-SO2Ra、-S(O)Ra又は-P(O)RaRb、又は0、1、2、又は3つの置換基によって置換されたC1-C6アルキル基、C3-C6シクロアルキル基、-O(C1-C6アルキル基)、-O(C0-C6アルキレン)(C5-C10アリール基)、-O(C0-C6アルキレン)(5-10員ヘテロアリール基)、O(C0-C6アルキレン)(C3-C6シクロアルキル基)又は-O(C0-C6アルキレン)(3-6員ヘテロシクロアルキル基) を表し、前記置換基は-ORa、シアノ基、オキソ、ハロゲン、C1-C6アルキル基、-(C1-C6アルキレン)ORa、シアノ基C1-C6アルキル基、C1-C6ハロアルキル基、C3-C8シクロアルキル基、-C(O)Ra、-(C1-C6アルキレン)C(O)Ra、-C(O)ORa、-(C1-C6アルキレン)C(O)ORa、-NRaRb、-(C1-C6アルキレン)NRaRb、-C(O)NRaRb、-SO2Ra、-C(O)NRaSO2Rb、-NRaC(O)Rbから選ばれ、
RLは水素、C1-C6アルキル基、-O(C1-C6アルキル基)、-O(C3-C6シクロアルキル基)、ハロゲン、ニトロ基、シアノ基、-NRaRb、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表し、
T、Aはそれぞれ独立して0、1、2、又は3つの置換基によって置換された-(C1-C6アルキル基)、-(C0-C6アルキレン)-(C3-C12シクロアルキル基)、-(C0-C6アルキレン)-(3-12員ヘテロシクロアルキル基)、-(C0-C6アルキレン)-(C6-C10アリール基)又は-(C0-C6アルキレン)-(5-10員ヘテロアリール基) を表し、前記置換基はシアノ基、オキソ、ハロゲン、C1-C6アルキル基、-(C0-C6アルキレン)ORa、シアノ基C1-C6アルキル基、ハロ(C1-C6アルキル基)、C3-C8シクロアルキル基、-(C0-C6アルキレン)C(O)Ra、-(C0-C6アルキレン)C(O)ORa、-(C0-C6アルケニル)C(O)ORa、(C0-C6アルキレン)NRaRb、-C(O)NRaRb、-NRaSO2Rb、-C(O)NRaSO2Rb、-NRaC(O)Rbから選ばれ、
RA、RBはそれぞれ独立して水素、C1-C6アルキル基、-(C0-C3アルキレン)(C3-C12シクロアルキル基)、-(C0-C3アルキレン)(3-12員ヘテロシクロアルキル基)、ハロ(C1-C6アルキル基)又はハロゲンを表し、または、RAとRBは、それらの共結合した炭素原子と一緒になって3~6員の環を形成し、
RC、RDはそれぞれ独立して水素、C1-C6アルキル基、-(C0-C3アルキレン)(C3-C12シクロアルキル基)、-(C0-C3アルキレン)(3-12員ヘテロシクロアルキル基)、ハロ(C1-C6アルキル基) 又はハロゲンを表し、又はは、RCとRDは、それらの共結合原子と一緒になって3~6員の環を形成し、
Ra、Rbはそれぞれ独立して水素、C1-C6アルキル基、ハロ(C1-C6アルキル基)、-(C0-C6アルキレン)OH、-(C0-C3アルキレン)(C3-C12シクロアルキル基)、-(C0-C3アルキレン)(3-12員ヘテロシクロアルキル基)、-(C0-C3アルキレン)(C6-C10員芳香環)、-(C0-C3アルキレン)(5-10員ヘテロ芳香環) 又はハロ(C1-C6アルキル基) を表し、又は、RaとRbは、それらの共結合原子と一緒になって3~6員の環を形成し、
m、oはそれぞれ独立して0、1又は2を表し、
p、qはそれぞれ独立して0、1、2又は3を表す、
式(I)の化合物又はその薬学的に許容される塩、プロドラッグ、同位体誘導体、異性体、溶媒和物、又はその代謝物。 - L1が、-CRARB-から選択され、RA、RBが、それぞれ独立して、水素、ハロゲン、C 1~C 6アルキルおよびハロ(C 1~C 6アルキル)から選択され、好ましくは水素である、請求項1~4のいずれか1項に記載の化合物。
- L2とL3はそれぞれ独立して-CRCRD-、-CRCRD-NRa- (CRCRD)q-から選ばれ、qは0、1又は2から選ばれ、RC、RDはそれぞれ独立して水素、ハロゲン、C1-C6アルキル基和ハロ(C1-C6アルキル基)から選ばれ、好ましくは水素であり、Raはそれぞれ独立して水素、C1-C6アルキル基、ハロ(C1-C6アルキル基)、-(C0-C3アルキレン)C3-C12シクロアルキル基から選ばれる、請求項1~4のいずれか1項に記載の化合物。
- W1、W2はそれぞれ独立してCH又はNを表す、請求項1~6のいずれか1項に記載の化合物。
- W3はCH又はNを表す、請求項3、5又は6のいずれか1項に記載の化合物。
- W4はCH又はNを表す、請求項4~6のいずれか1項に記載の化合物。
- T、Aはそれぞれ独立して0、1、2、又は3つの置換基によって置換された:-(C1-C6アルキル基)、-(C0-C6アルキレン)-(C3-C12シクロアルキル基)又は-(C0-C6アルキレン)-(3-12員ヘテロシクロアルキル基)を表す、前記置換基はシアノ基、オキソ、ハロゲン、C1-C6アルキル基、-(C0-C6アルキレン)ORa、シアノ基C1-C6アルキル基、ハロ(C1-C6アルキル基)、C3-C8シクロアルキル基、-(C0-C6アルキレン)C(O)Ra、-(C0-C6アルキレン)C(O)ORa、-(C0-C6アルケニル)C(O)ORa、-(C0-C6アルキレン)NRaRb、-C(O)NRaRb、-NRaSO2Rb、-C(O)NRaSO2Rb、-NRaC(O)Rbから選ばれ、Ra、Rbはそれぞれ独立して水素、C1-C6アルキル基又はハロ(C1-C6アルキル基) を表す、請求項1~9のいずれか1項に記載の化合物。
- T、Aはそれぞれ独立して0、1又は2つの置換基によって置換されたC1-C6アルキル基、C3-C12シクロアルキル基又は3-12員ヘテロシクロアルキル基を表し、前記置換基はシアノ基、オキソ、-ORa、-(C0-C6アルキレン)C(O)ORa、-(C0-C6アルケニル)C(O)ORa、-NRaSO2Rb、-C(O)NRaSO2Rb和-NRaC(O)Rbから選ばれ、Ra、Rbはそれぞれ独立して水素、C1-C6アルキル基又はハロ(C1-C6アルキル基) を表す、請求項10に記載の化合物。
- R1は0、1、2、又は3つの置換基によって置換された-O(C1-C6アルキル基)、-O(C0-C6アルキレン)(C5-C10アリール基)、-O(C0-C6アルキレン)(5-10員ヘテロアリール基)、-O(C0-C6アルキレン)(C3-C6シクロアルキル基)又は-O(C0-C6アルキレン)(3-6員ヘテロシクロアルキル基) を表し、前記置換基はシアノ基、オキソ、ハロゲン、シアノ基C1-C6アルキル基とC1-C6ハロアルキル基から選ばれる。
- R2は水素、ハロゲン、ニトロ基、シアノ基、-SO2Ra、C1-C6アルキル基、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表し、Raは水素、C1-C6アルキル基又はハロ(C1-C6アルキル基) を表す、請求項1~16のいずれか1項に記載の化合物。
- R3、R4はそれぞれ独立して水素、ハロゲン、ニトロ基又はシアノ基を表す、請求項1~16のいずれか1項に記載の化合物。
- R5は水素、ハロゲン、ニトロ基、シアノ基、C1-C6アルキル基、ハロ(C1-C6アルキル基)又はC3-C6シクロアルキル基を表す、請求項1~16のいずれか1項に記載の化合物。
- R6は水素、ハロゲン、ニトロ基、シアノ基、-SO2Ra、C1-C6アルキル基、ハロ(C1-C6アルキル基) 又はC3-C6シクロアルキル基又は0、1、2、又は3つの置換基によって置換された-O(C1-C6アルキル基)、-O(C0-C6アルキレン)(C5-C10アリール基)、-O(C0-C6アルキレン)(5-10員ヘテロアリール基)、-O(C0-C6アルキレン)(C3-C6シクロアルキル基)又は-O(C0-C6アルキレン)(3-6員ヘテロシクロアルキル基) を表し、前記置換基はシアノ基、オキソ、ハロゲン、シアノ基C1-C6アルキル基とC1-C6ハロアルキル基から選ばれる、請求項1~16のいずれか1項に記載の化合物。
- RLは水素又はハロゲンを表す、請求項1~21のいずれか1項に記載の化合物。
- RM、RNはそれぞれ独立して水素を表す、請求項1~21のいずれか1項に記載の化合物。
- 請求項1~24のいずれか一項に記載の化合物および場合により薬学的に許容される担体を含む医薬組成物。
- PD-L1とPD-1との結合の阻害に応答する疾患又は状態を予防又は治療するための医薬の製造における、請求項1~24のいずれか一項に記載の化合物又は請求項25に記載の医薬組成物の使用。
- 前記疾患又は状態が、腫瘍、癌、ウイルス感染、炎症関連疾患、および自己免疫疾患からなる群から選択される、請求項26に記載の使用。
- PD-L1のPD-1への結合の阻害に応答する疾患又は状態を治療する方法であって、それを必要とする哺乳動物に、請求項1~24のいずれか一項に記載の化合物を、請求項25に記載の医療用組成物を投与することを含む方法。
- 請求項1~24のいずれか一項に記載の化合物又は請求項25に記載の医療用組成物を前記PD-L1および/又はPD-1に曝露することを含む、PD-L1およびPD-1の結合を阻害する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911368320 | 2019-12-26 | ||
CN201911368320.1 | 2019-12-26 | ||
PCT/CN2020/138157 WO2021129584A1 (zh) | 2019-12-26 | 2020-12-22 | Pd-l1拮抗剂化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022552693A true JP2022552693A (ja) | 2022-12-19 |
Family
ID=76574838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022522850A Pending JP2022552693A (ja) | 2019-12-26 | 2020-12-22 | Pd-l1拮抗薬化合物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230054028A1 (ja) |
EP (1) | EP4083032A4 (ja) |
JP (1) | JP2022552693A (ja) |
KR (1) | KR20220121254A (ja) |
CN (1) | CN115066423B (ja) |
AU (1) | AU2020413555A1 (ja) |
BR (1) | BR112022012737A2 (ja) |
CA (1) | CA3160606A1 (ja) |
IL (1) | IL294209A (ja) |
MX (1) | MX2022008016A (ja) |
WO (1) | WO2021129584A1 (ja) |
ZA (1) | ZA202206266B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023250335A1 (en) * | 2022-06-21 | 2023-12-28 | Chulalongkorn University | 1,4-diphenyl-1 h-indazole and 1-pyridin-2-yl-4-phenyl-1 h-indazole derivatives as pd-1/pd-l1 modulators for the treatment of cancer |
CN115611700A (zh) * | 2022-10-11 | 2023-01-17 | 辽宁东大光明化工科技有限责任公司 | 一种1-溴-2,5-二氯-3-氟苯的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102276644B1 (ko) * | 2013-09-04 | 2021-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조절제로서 유용한 화합물 |
US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
US10590105B2 (en) * | 2016-07-08 | 2020-03-17 | Bristol-Meyers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
JOP20180040A1 (ar) * | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
CN109665968B (zh) * | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
JP7281834B2 (ja) * | 2019-02-21 | 2023-05-26 | アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド | Pd-l1拮抗薬化合物 |
-
2020
- 2020-12-22 CN CN202080079596.2A patent/CN115066423B/zh active Active
- 2020-12-22 WO PCT/CN2020/138157 patent/WO2021129584A1/zh active Application Filing
- 2020-12-22 EP EP20907871.6A patent/EP4083032A4/en active Pending
- 2020-12-22 AU AU2020413555A patent/AU2020413555A1/en active Pending
- 2020-12-22 CA CA3160606A patent/CA3160606A1/en active Pending
- 2020-12-22 US US17/780,979 patent/US20230054028A1/en active Pending
- 2020-12-22 MX MX2022008016A patent/MX2022008016A/es unknown
- 2020-12-22 BR BR112022012737A patent/BR112022012737A2/pt active Search and Examination
- 2020-12-22 KR KR1020227025665A patent/KR20220121254A/ko unknown
- 2020-12-22 JP JP2022522850A patent/JP2022552693A/ja active Pending
- 2020-12-22 IL IL294209A patent/IL294209A/en unknown
-
2022
- 2022-06-06 ZA ZA2022/06266A patent/ZA202206266B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115066423B (zh) | 2024-02-02 |
CN115066423A (zh) | 2022-09-16 |
ZA202206266B (en) | 2023-11-29 |
US20230054028A1 (en) | 2023-02-23 |
KR20220121254A (ko) | 2022-08-31 |
EP4083032A4 (en) | 2023-10-25 |
IL294209A (en) | 2022-08-01 |
AU2020413555A1 (en) | 2022-06-30 |
MX2022008016A (es) | 2022-07-27 |
WO2021129584A1 (zh) | 2021-07-01 |
BR112022012737A2 (pt) | 2022-09-06 |
CA3160606A1 (en) | 2021-07-01 |
EP4083032A1 (en) | 2022-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7125385B2 (ja) | Tlr7/8アンタゴニストおよびそれらの使用 | |
TWI804003B (zh) | Tlr7/8拮抗劑及其用途 | |
EP3655401B1 (en) | Tlr7/8 antagonists and uses thereof | |
JP7166028B2 (ja) | 高活性stingタンパク質アゴニスト化合物 | |
KR20220092920A (ko) | 헬리오스의 소분자 분해제 및 사용 방법 | |
WO2019158070A1 (zh) | A2a和/或a2b受体拮抗剂 | |
JP2021534250A (ja) | 高活性stingタンパク質アゴニスト | |
EP3744718A1 (en) | Highly active csf1r inhibitor compound | |
WO2019141153A1 (zh) | 吲哚胺2,3-双加氧酶抑制剂及其用途 | |
JP2022552693A (ja) | Pd-l1拮抗薬化合物 | |
JP7281834B2 (ja) | Pd-l1拮抗薬化合物 | |
JP7436630B2 (ja) | アデノシン受容体拮抗薬 | |
WO2022089398A1 (zh) | 一种高活性的hpk1激酶抑制剂 | |
JP7299411B2 (ja) | アデノシン受容体拮抗薬 | |
TWI768781B (zh) | 轉化生長因子-β受體抑制劑 | |
TWI810547B (zh) | Pd-l1拮抗劑化合物 | |
LU505117B1 (en) | A pan-KRAS inhibitor compound | |
WO2022199561A1 (zh) | Hpk1激酶抑制剂化合物 | |
TW202304906A (zh) | 高活性hpk1激酶抑制劑 | |
TW202333697A (zh) | Wnt通路抑制劑化合物 | |
CN118047799A (zh) | 一种pan-KRAS抑制剂化合物 | |
CN118047797A (zh) | 一种pan-KRAS抑制剂化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220415 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220415 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240222 |